Appendix CList of Excluded Studies

Publication Details

A total of 921 studies were excluded from the review during phase 2 screening. Reasons for exclusion included: a) publication type or study design (n = 612), b) non-English language (n = 100), c) population or intervention not of interest (n = 134), d) no extractable data related to the outcome of interest (n = 58), and e) publication unavailable through library service (n = 17).

Publication Type and Study Design

1.
Abdollahian EM. Comparing the effects of risperidone and haloperidol in chronic schizophrenic patients. Proceedings of the Thematic Conference of the World Psychiatric Association on “Treatments in Psychiatry: An Update”;; 2004.
2.
Addington J, Addington D. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. Can J Psychiatry. 1997;42(9):983. [PubMed: 9429073]
3.
Addington J. Cognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. 27th Collegium Internationale Neuro-psychopharmacologicum; 2006.
4.
Adetunji B, Basil B, Mathews M, et al. Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate. J Clin Psychiatry. 2006;67(3):497–8. [PubMed: 16649843]
5.
Agelink MW, Malessa R, Kamcili E, et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome? Neuropsychobiology. 1998;38(1):19–24. [PubMed: 9701718]
6.
Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry. 2003;60(12):1228–35. [PubMed: 14662555]
7.
Aleman A, Kahn RS. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol. 2001;11(4):289–93. [PubMed: 11532383]
8.
Allan ER, Sison CE, Alpert M, et al. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull. 1998;34(1):71–4. [PubMed: 9564201]
9.
Allison DB, Loebel AD, Lombardo I, et al. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res. 2009;170(2–3):172–6. [PubMed: 19897253]
10.
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96. [PubMed: 10553730]
11.
Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547–62. [PubMed: 18547125]
12.
Amann BL, Pogarell O, Mergl R, et al. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol. 2003;18(8):641–6. [PubMed: 14696024]
13.
Ames D, Wirshing WC, Baker RW, et al. Predictive value of eosinophilia for neutropenia during clozapine treatment. J Clin Psychiatry. 1996;57(12):579–81. [PubMed: 9010121]
14.
Ames D. Risperidone vs. haloperidol: relative liabilities for ocd and depression. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia; 1996. p. 129.
15.
Ames D. Subjective response to risperidone and haloperidol: preliminary results conference proceeding. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia; 1996. p. 129.
16.
Ames D. Treatment resistant schizophrenia: evaluation of risperidone vs. haloperidol. Biol Psychiatry. 1997:72S–3S.
17.
Ames D. Treatment-resistant schizophrenia: efficacy of risperidone versus haloperidol. 150th Annual Meeting of the American Psychiatric Association; 2000.
18.
Amin M, Shukla VS. Olanzapine vs haloperidol for treatment of schizophrenia. JAMA. 2004;291(9):1065–6. [PubMed: 14996767]
19.
Andersen SW, Tollefson GD, Sanger TM. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Schizophr Res. 1999;269 [conference abstract] [PubMed: 9510219]
20.
Andrade C. A mood stabilizer with risperidone or haloperidol for mania. Am J Psychiatry. 2004;161(11):2140. [PubMed: 15514435]
21.
Anutosh S, Ali MW, Ingenito Controlled study of aripiprazole and haloperidol in schizophrenia. Eur Psychiatry. 2002;(Suppl 1):103s.
22.
Arbaizar B, Gomez-Acebo I, Llorca J. Quality of reporting controlled clinical trials on treatment of the acute mania phase of bipolar disorder with new antipsychotic drugs. Pharmacopsychiatry. 2008;41(6):240–1. [PubMed: 19067261]
23.
Arranz B. Does the intracellular signalling system associated to the serotonergic 5-HT2A receptor activation predict clinical response to olanzapine in drug-free schizophrenic patients? Eur Neuropsychopharmacol. 2002;(Suppl 3):S266.
24.
Ascher-Svanum H, Nyhuis A, Tunis S, et al. Time to all cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia. 158th Annual Meeting of the American Psychiatric Association; 2005.
25.
Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163–71. [PMC free article: PMC2632496] [PubMed: 18156640]
26.
AstraZeneca. A multicenter, double-blind, randomized, comparison of quetiapine (seroquelA) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia. http://www​.clinicalstudyresults.org/
27.
AstraZeneca. A multicentre, double-blind, randomised trial to compare the effects of seroquel and chlorpromazine in patients with treatment resistant schizophrenia (5077IL/0054 TRESS). http://www​.clinicalstudyresults.org/2000.
28.
AstraZeneca. An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel (Quetiapine Fumarate) and Haloperidol as Monotherapy in the Treatment of Acute Mania [5077IL/0104]. http://www​.clinicalstudyresults.org/
29.
AstraZeneca. An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel (Quetiapine Fumarate) and Haloperidol as Monotherapy in the Treatment of Acute Mania [5077IL/0104]. http://www​.clinicalstudyresults.org/
30.
Atmaca M. The comparison of quetiapine and haloperidol effects on serum prolactine in patients with schizophrenia. Eur Neuropsychopharmacol. 2001;11(3):S240.
31.
Attari A, Amini M, Mansoori S, et al. Comparison of incidence of diabetes mellitus in schizophrenic patients treated with atypical or typical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2009:S84.
32.
Avissar S, Roitman G, Schreiber G. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cell Mol Neurobiol. 2001;21(6):799–811. [PubMed: 12043849]
33.
Awad AG, Voruganti LN, Mackell JA, et al. Ziprasidone versus haloperidol in acute schizophrenia: subjective tolerability. 156th Annual Meeting of the American Psychiatric Association; San Francisco CA. 2003.
34.
Ayd FJ. Aripiprazole: recent evidence-based clinical data. Int Drug Ther Newsl. 2003;38(5)
35.
Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201–9. [PubMed: 18338766]
36.
Bagnall A, Kleijnen J, Leitner M, et al. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2010;2010(5) [systematic review] [PubMed: 10796670]
37.
Baker RW, Julier BE, Stauffer VL. Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo. Eur Neuropsychopharmacol. 2001;11(Suppl 3):S278–S279.
38.
Barak Y, Swartz M, Plopsky I. Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol. 2005;20(6):315–7. [PubMed: 16192840]
39.
Barbui C. “Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial”: comment. The American Journal of Psychiatry. 1998;155(1):152–3. [PubMed: 9433358]
40.
Barbui C. Randomized evaluation of the effectiveness of clozapine and aripiprazole versus clozapine and haloperidol in the treatment of schizophrenia: an independent, pragmatic, multicentre, parallel-group, superiority trial. http://www​.clinicaltrials.gov.
41.
Bartzokis G, Lu PH, Nuechterlein KH, et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res. 2007;93(1–3):13–22. [PMC free article: PMC1974878] [PubMed: 17407804]
42.
Basil B, Mathews M, Adetunji B, et al. The CATIE study. Am J Psychiatry. 2006;163(3):555. [PubMed: 16513895]
43.
Basson B. Factors influencing weight change in patients with schizophrenia treated with olanzapine verus haloperidol or risperidone. J Psychopharmacol. 2000;(3 Suppl):A60.
44.
Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62(4):231–8. [PubMed: 11379836]
45.
Basu A, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. Stat Med. 2006;25(17):2886–910. [PubMed: 16220519]
46.
Battaglia J, Houston JP, Ahl J, et al. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clin Ther. 2005;27(10):1612–8. [PubMed: 16330297]
47.
Battaglia J, Lindborg SR, Alaka K, et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003;21(3):192–8. [PubMed: 12811711]
48.
Bayar R. A multi-centered study evaluating the effects of haloperidol and olanzapine on depressive symptoms in schizophrenic patients. Eur Neuropsychopharmacol. 2005;(Suppl 3):S474.
49.
Beasley C. Olanzapine versus haloperidol: long-term results of the multi-center international trial. Eur Neuropsychopharmacol. 1996;6(Suppl 3):59.
50.
Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999;174:23–30. [PubMed: 10211147]
51.
Beasley CM, Stauffer VL, Liu-Seifert H, et al. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol. 2007;27(3):252–8. [PubMed: 17502771]
52.
Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry. 1997;58(Suppl 10):7–12. [PubMed: 9265910]
53.
Bech P, Peuskens JC, Marder SR, et al. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Eur Psychiatry. 1998;13(6):310–4. [PubMed: 19698646]
54.
Bedard MA, Scherer H, Delorimier J, et al. Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. Can J Psychiatry. 1996;41(7 Suppl1) [PubMed: 8884048]
55.
Beitinger R, Lin J, Kissling W, et al. Comparative remission rates of schizophrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1643–51. [PubMed: 18616969]
56.
Berk M, Ng F, Wang WV, et al. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affective Disord. 2008;110(1–2):126–34. [PubMed: 18280579]
57.
Bersani G, Gherardelli S, Clemente R, et al. Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol. 2005;25(4):372–5. [PubMed: 16012282]
58.
Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111–61. [PubMed: 11217867]
59.
Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2010 [systematic review] [PubMed: 18646161]
60.
Bhattacharjee J, El-Sayeh HGG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008 [PubMed: 18646161]
61.
Birkett DP. Clozapine compared with haloperidol for refractory schizophrenia. New Engl J Med. 1998;338(4):267–8. [PubMed: 9441246]
62.
Blin O. Anxiolytic profiles of levomepromazine, haloperidol and risperidone in 62 schizophrenic patients. Clin Pharmacol Ther. 1992;(2):189.
63.
Blin O. Anxiolytic profiles of risperidone, haloperidol, and levomepromazine in schizophrenia: a factorial and regression analysis. Proceedings of the 9th World Congress of Psychiatry; 1993. p. 12.
64.
Blin O. Comparison of anxiolytic properties of levomepromazine, haloperidol and risperidone in schizophrenic patients. Biol Psychiatry. 1991;29:388.
65.
Blin O. Comparison of risperidone, haloperidol and levomepromazine in schizophrenia: a factorial analysis and discriminant function analysis. Clin Neuropharmacol. 1992;16(Suppl 1. Pt B):9B.
66.
Bobes J, Garc AP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125–47. [PubMed: 12623765]
67.
Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003;62(1–2):77–88. [PubMed: 12765747]
68.
Bonham C, Abbott C. Are second generation antipsychotics a distinct class? J Psychiatr Pract. 2008;14(4):225–31. [PMC free article: PMC3632396] [PubMed: 18664891]
69.
Borison R. Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Proceedings of the 1st International Risperidone Investigators’ Meeting;; 1992. pp. 1992–10.
70.
Borison RL, Arvanitist LA, Miller BG. A comparison of five fixed doses ‘seroquel’ (Ici 204,636) With haloperidol and placebo in patients with schizophrenia conference proceeding. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia; 2000. p. 132.
71.
Bouchard RH, Demers MF, Merette Classical neuroleptics (CNLP) vs risperdone (RIS) interim 12 months efficacy of a long-term, naturalistic study in schizophrenics. 11th CINP Congress; Glasgow, Scotland. 1998.
72.
Bourin M. Aripiprazole versus haloperidol for maintained treatment effect in acute mania. 156th Annual Meeting of the American Psychiatric Association; San Francisco, CA. 2000.
73.
Bourin M. Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. 16th Congress of the European College of Neuropsychopharmacology; 2003.
74.
Bowden CL, Ketter TA, Sachs GS. Acute mania treatment. J Clin Psychiatry. 2005;66(12):1598–601. [PubMed: 16401164]
75.
Brahm NC, Gutierres SL, Carnahan RM. Quetiapine for acute mania in bipolar disorder. Am J Health-Syst Pharm. 2007;64(10):1045–53. [PubMed: 17494904]
76.
Brambilla P, Barale F, Caverzasi E, et al. Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. Int Clin Psychopharmacol. 2002;17(4):189–95. [PubMed: 12131603]
77.
Brecher M. Prolactin levels and adverse events in patients treated with risperidone. Sixth World Congress of Biological Psychiatry; Nice, France. 1997. p. 173S.
78.
Brecher MB, Lemmens P. Tolerability and cardiovascular safety of risperidone. 150th Annual Meeting of the American Psychiatric Association; San Diego, CA. 1997.
79.
Breier A. A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000. p. 14.
80.
Breier A. A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia. Schizophr Res. 2003:274–5. [PubMed: 16202565]
81.
Breier A. Comparative efficacy of olanzapne and haloperidol for patients with treatment resistant schizophrenia. Schizophr Res. 1999;(1–3):271. [PubMed: 10071708]
82.
Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2001;8(19):iii–iiv. [PubMed: 15147609]
83.
Bristol-Myers S. A multicenter, randomized, double-blind study of flexible doses of aripiprazole versus perphenazine in the treatment of patients with treatment-resistant schizophrenia. http:​//wwwclinicalstudyresultsorg/
84.
Bristol-Myers S. A multicenter, randomized, double-blind study of aripiprazole and haloperidol in the maintained response to treatment for an acute manic episode. http://www​.clinicalstudyresults.org/
85.
Bristol-Myers S. A randomized, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder. http://www​.clinicalstudyresults.org/
86.
Brook SJ. Ziprasidone vs haloperidol for IM/oral therapy of acute schizophrenia. Proceedings of the 11th Congress of the Association of European Psychiatrists; 2002. p. 100s.
87.
Brook SK. The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, non-organic psychosis. 151st American Psychiatric Association Meeting; 1998.
88.
Brook SK. The efficacy and tolerability of intramuscular (Im) Ziprasidone versus im haloperidol in patients with acute, nonorganic pyschosis conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe, New Mexico USA. 1999. pp. 17–21. 1999.
89.
Brook SW. IM/oral ziprasidone versus haloperidol in recent-onset schizophrenia. Proceedings of the 3rd International Conference on Early Psychosis; 2002. p. 28.
90.
Brook SW. Sequential IM/oral ziprasidone versus haloperidol in schizophrenia with anxiety. Schizophr Res. 2003
91.
Brook SW. Sequential IM/oral ziprasidone vs haloperidol in severe schizophrenia. Eur Neuropsychopharmacol. 2002;(Suppl 3):S291.
92.
Brook SW. Sequential im/oral ziprasidone vs IM/oral haloperidol in patients with severe schizophrenia. Int J Neuropsychopharmacol. 2002;(Suppl 1):S124.
93.
Brook SW. Ziprasidone vs. haloperidol in sequential IM or oral treatment of acute schizophrenia. Schizophr Res. 2002;(3 Suppl 1):181.
94.
Brook S. Ziprasidone vs haloperidol in sequential IM/oral treatment of acute schizophrenia. Eur Neuropsychopharmacol. 2001;(3):275.
95.
Brown ES. Management of comorbid bipolar disorder and substance abuse. J Clin Psychiatry. 2006;67(8):e05. [PubMed: 17107268]
96.
Buchanan RW, Breier A, Kirkparrick B, et al. Clozapine versus haloperidol in the treatment of schizophrenic patients. J Am Osteopath Assoc. 1998;98(7):366.
97.
Buchsbaum MS, Potkin SG, Marshall JF, et al. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology. 1992;6(3):155–63. [PubMed: 1599606]
98.
Buckley P. Comparison of the effect of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry; 2001.
99.
Buckley PF, Goldstein JM, Emsley RA. Comparison of quetiapine and haloperidol in treatment-resistant schizophrenia. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001.
100.
Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry. 2004;184(Suppl47):s87–s93. [PubMed: 15056600]
101.
Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68(11):1682–90. [PubMed: 18052561]
102.
Bustillo J. Differential brain effects of chronic exposure to haloperidol and quetiapine in antipsychotic-naive schizophrenia: a longitudinal protonmagnetic resonance spectroscopy study. Schizophr Res. 2001;49(1,2):192.
103.
Bustillo JR, Lauriello J, Rowland LM, et al. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001;107(3):135–49. [PubMed: 11566430]
104.
Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: Iloperidone. Drug Des Dev Ther. 2010;(4):33–48. [PMC free article: PMC2846148] [PubMed: 20368905]
105.
Campbell DB, Ebert PJ, Skelly T, et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry. 2008;63(1):32–41. [PMC free article: PMC2194758] [PubMed: 17588543]
106.
Canas F, Perez-Sola V, Diaz S, et al. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. Clin Drug Invest. 2007;27(9):633–45. [PubMed: 17705572]
107.
Cantillon M. Quetiapine fumarate reduces aggression conference abstract. 11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998.
108.
Cardoni AA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother. 1995;29(6):610–8. [PubMed: 7545034]
109.
Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry. 2003;64(8):898–906. [PubMed: 12927004]
110.
Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995;10(4):207–13. [PubMed: 8748041]
111.
Carson WH, Ali M. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000. p. 14.
112.
Carson WH, Kane JM. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Eur Neuropsychopharmacol. 2000;10(Suppl3):S309.
113.
Carson WH, Pigott TA, Saha AR. Aripirazole versus placebo in the treatment of chronic schizophrenia. XXIII Collegium Internationale Neuro-Psychopharmacologium (CINP) Congress; Montreal. 2002. [poster]
114.
Casademont J, Garrabou G, Miro O, et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol. 2007;27(3):284–8. [PubMed: 17502776]
115.
Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr. 2006;11(7:Suppl 7):25–31. [PubMed: 16816797]
116.
Cavazzoni P, Mukhopadhyay N, Carlson C, et al. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. Br J Psychiatry Suppl. 2004;47:S94–101. [PubMed: 15056601]
117.
Cavazzoni P. An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine. Schizophr Res. 2002;(3 Suppl 1):171.
118.
Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006;67(1):107–13. [PubMed: 16426096]
119.
Cavezzoni P. An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, ri. Int J Neuropsychopharmacol. 2002;(Suppl 1):S164.
120.
Centorrino F. Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia. Schizophr Res. 2003
121.
Central SU. Efficacy and safety of risperidone oral solution combination clonazepam versus haloperidol intramuscular (IM) injection for treatment of acute psychotic agitation in schizophrenia. http://www​.clinical.trials.gov.
122.
Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158(4):518–26. [PubMed: 11282684]
123.
Chakrabarti A, Bagnall A, Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007;(4):CD001943. [PubMed: 17943763]
124.
Chaudhry HR, Kongsakon RI. Quality of life and clinical outcomes for Asian outpatients with schizophrenia: a double-blind randomised comparison of olanzapine and haloperidol. Eur Neuropsychopharmacol. 2003;(4):S309.
125.
Cheer SM, Wagstaff AJ. Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(3):173–99. [PubMed: 14871161]
126.
Cheine MV, Wahlbeck K, Rimon R. Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. Int J Psychiatr Clin Pract. 1999;3(3):159–69. [PubMed: 24927201]
127.
Choi KH, Higgs BW, Weis S, et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry. 2009;9:57. [PMC free article: PMC2749837] [PubMed: 19758435]
128.
Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997;17(4):298–307. [PubMed: 9241010]
129.
Cipriani A, Rendell JM, Geddes J. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev. 2009;2009(1) [systematic review] [PubMed: 16856043]
130.
Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2(4):427–43. [PMC free article: PMC2671949] [PubMed: 19412492]
131.
Citrome L. Interpreting and applying the CATIE results: With CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. Psychiatry (USA) 2007;4(10):23–9. [PMC free article: PMC2860523] [PubMed: 20428308]
132.
Clouth J. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999. p. 20.
133.
Cohen D, Correll C, de HM. Do antipsychotic medications reduce or increase mortality in schizophrenia?: a critical apprisal of the FIN-11 study. Schizophr Res. 2010;270 [PubMed: 20060684]
134.
Coleman CI, White CM. The impact of antipsychotic agent choice on the risk of coronary heart disease mortality due to cholesterol effects. Formulary. 2007;42(1):62–5.
135.
Conley RR, Tamminga CA, Beasley Olanzapine vs chlorpromazine in therapy related-refractory schizophrenia. Schizophrenia Research (Special Issue) - The VIth International Congress on Schizophrenia Research; 1997.
136.
Conley RR, Tamminga CA, Beasley Olanzapine vs chlorpromazine in therapy-refractory schizophrenia. Schizophr Res. 1997;24(1,2):190.
137.
Conley RR, Tamminga CA, Beasley Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Biol Psychiatry. 1997;41:73S.
138.
Conley RR. New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia. http://www​.clinicaltrials.gov/
139.
Conte G. Long-term risperidone versus haloperidol plus mood stabilisers in psychotic bipolar disorder. Int J Neuropsychopharmacol. 2002;(Suppl 1):S109.
140.
Conus P. Comparison of combination olanzapine and lithium and combination chlorpromazine and lithium in the treatment of a first manic episode with psychotic features. www​.Controlled-Trials.com/
141.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25. [PubMed: 14992963]
142.
Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–57. [PMC free article: PMC2659301] [PubMed: 18417466]
143.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6. [PubMed: 18332662]
144.
Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999;14(4):209–18. [PubMed: 10468313]
145.
Crawford AMK, Gomez JC, Beasley CM, et al. Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial. Eur Neuropsychopharmacol. 1999;9(5):276.
146.
Crocket G. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: UK centres in an international dose finding study. Proceedings of the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1992. p. 197.
147.
Csernansky J. A long term double blind comparison of risperidone and haloperidol in stable outpatients with schizophrenia or schizoaffective disorder. Int J Neuropsychopharmacol. 2000;(Suppl 1):S155.
148.
Csernansky J. Risperidone vs haloperidol: relapse prevention in schizophrenia. XI World Congress of Psychiatry; Hamburg. August 6–11, 2000.
149.
Csernansky JG, Okamoto A, Brecher MB. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorder: a long-term, double-blind comparison. Proceedings of the 51st Institute on Psychiatric Services; 1999. p. 110.
150.
Csernansky JG, Okamoto A. Risperidone versus haloperidol for prevention of relapse in patients with schizophrenia and schizoaffective disorder: a long-term double blind comparison. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999. p. 16.
151.
Csernansky JG, Okamoto A. Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long-term double-blind comparison. Biol Psychiatry. 2000:32S.
152.
Csernansky JG, Okamoto A. Risperidone vs haloperidol: prevention of relapse in schizophrenia. Eur Neuropsychopharmacol. 1999
153.
Cucchiaro J. A randomized, double-blind, multicenter phase iii study of iloperidone versus haloperidol and placebo in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2001;(1,2):223–4.
154.
Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48(1):17–28. [PubMed: 11278151]
155.
Czekalla J, Beasley CM Jr, Dellva MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001;62(3):191–8. [PubMed: 11305706]
156.
Czekalla J. Olanzapine versus haloperidol: a randomized, double-blind cross over study with 31p-nuclear magnetic resonance spectroscopy MRS and regional cerebral blood flow measurements fMRI of the dorsolateral prefrontal cortex dlpfc in schizophrenics. Schizophr Res. 2002;(3 Suppl 1):180.
157.
Czobor P, Volavka J. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. J Clin Psychopharmacol. 1993;13(5):332–42. [PubMed: 7693770]
158.
Daniel DG, Stock EG, Wilber CH, et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; New York, USA. 2004.
159.
David AS, Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes. Health Technol Assess (Rockv) 2001;5(34):1–61. [PubMed: 11809126]
160.
David SR, Meehan k. Intramuscular olanzapine versus intramuscular haloperidol and intramuscular placebo: an international double-blind study in acutely agitated patients with schizophrenia. Schizophr Res. 2001;(1,2):224.
161.
David SR, Purdon S, Jones BD, et al. Olanzapine versus risperidone versus haloperidol in early illness schizophrenia: education improves outcomes in MDD. 152nd Annual Meeting of the American Psychiatric Association; 1999.
162.
David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22(9):1085–96. [PubMed: 11048906]
163.
Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST): correction. The American Journal of Psychiatry. 2009;166(6):731. [PubMed: 19369319]
164.
Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: meta-analysis of efficacy and safety. Clin Ther. 1998;20(1):58–71. [PubMed: 9522104]
165.
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry. 2003;60(6):553–64. [PubMed: 12796218]
166.
Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull. 2002;28(1):43–61. [PubMed: 12047021]
167.
Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62(10):757–71. [PubMed: 11816864]
168.
Davis L. To determine if olanzapine is more cost effective than haloperidol for the treatment of schizophrenia: the clinical and economic impact of olanzapine in the treatment of schizophrenia. National Institutes of Health. 2010;2001
169.
De CH, Claus A. Risperidone vs haloperidol in chronic schizophrenia: treatment outcome and correlates with VBR. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2010. pp. 1990–14.
170.
De CH, Malfroid M. Risperidone versus haloperidol in chronic schizophrenic patients: a 12 week multicenter double-blind parallel study. Psychopharmacology (Berl) 1988;(Suppl 1):348.
171.
De HL, van BN. Olanzapine and haloperidol for residual symptoms. Am J Psychiatry. 2005;162(7):1392–3. [PubMed: 15994737]
172.
De HL, van BN. Olanzapine vs haloperidol for treatment of schizophrenia. JAMA. 2004;291(9):1065–6. [PubMed: 14996769]
173.
de HL, van Bruggen Subjective experience and d2 receptor occupancy in patients with schizophrenia, treated with low dose olanzapine or haloperidol; a randomized double-blind study. Schizophr Res. 2002;(3 Suppl 1):179. [PubMed: 12562577]
174.
de Oliveira I, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther. 1996;21(5):349–58. [PubMed: 9119918]
175.
de Oliveira I. Risperidone vs. haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. XXth Collegium Internationale Neuro-psychopharmacologicum; 2006; Melbourne, Australia. [PubMed: 9119918]
176.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649–66. [PubMed: 15220010]
177.
Dellva M, Satterlee W, Tran P, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment. 9th European College of Neuropsychopharmacology Congress; 1996.
178.
Dellva MA, Beasley CM, Kuntz AJ, et al. What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?. 11th Annual Meeting of the American Association for Geriatric Psychiatry; 2000.
179.
Den BJ, Westenberg HG, Jansen AA. Risperidone in the treatment of chronic schizophrenia: a double blind comparative study with haloperidol. Clin Neuropharmacol. 1992;15(Suppl 1 Pt B):118.
180.
DeSilva P, Fenton M, Rathbone J. Zotepine for schizophrenia. Cochrane Database Syst Rev. 2006;2009(1) [systematic review] [PubMed: 17054149]
181.
Dillenschneider A. Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients. Eur Neuropsychopharmacol. 2005;(Suppl 3):S509.
182.
Dolnak DR, Minn K. Olanzapine versus haloperidol in the treatment of schizophrenia. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 2010. pp. 1996–9.
183.
Dossenbach M, Treuer T, Kryzhanovskaya L, et al. Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol. 2007;27(4):329–37. [PubMed: 17632215]
184.
Dossenbach M. Olanzapine versus fluphenazine - six weeks treatment of acute schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 2010. pp. 1997–17.
185.
Dossenbach M. Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. Eur Neuropsychopharmacol. 2000;(Suppl 3):S328–S329.
186.
Duarte A. Risperidone vs haloperidol in schizophrenic patients: Argentine results. Proceedings of the 9th World Congress of Psychiatry; 1993. p. 335.
187.
Dubitsky GM, Harris R. Abilify (aripiprazole) tablets, medical review part 1. U S Food and Drug Administration CDER. 2002:1–50.
188.
Duggan L, Brylewski J. Antipsychotic medication for those with both schizophrenia and learning disability. Cochrane Database Syst Rev. 2001;(3) [PubMed: 11686948]
189.
Duggan L, Fenton M, Rathbone J, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2009;2009(4) [PubMed: 15846619]
190.
Duncan E, Szilagyi S, Schwartz M, et al. Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiatry Res. 2003;120(1):1–12. [PubMed: 14500109]
191.
Duncan EJ, Woolson SL, Hamer RM, et al. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a veterans affairs population. Int Clin Psychopharmacol. 2009;24(4):204–13. [PubMed: 19494785]
192.
Eli L. A double-blind dose-response study comparing short acting intramuscular olanzapine, short acting intramuscular haloperidol, and intramuscular placebo in patients with schizophrenia. http:​//wwwclinicalstudyresultsorg/2010.
193.
Eli L. A double-blind randomized comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in acutely agitated patients with schizophrenia. http://www​.clinicaltrials.gov/2010. [PubMed: 24743717]
194.
Eli L. A double-blind randomized comparison of the efficacy and safety of short acting intramuscular olanzapine, short acting intramuscular haloperidol and intramuscular placebo in patients with schizophrenia. http:​//wwwclinicalstudyresultsorg/2010.
195.
Eli L. A fixed-dose range safety and efficacy study of olanzapine versus haloperidol in the treatment of schizophrenia. http:​//wwwclinicalstudyresultsorg/2010.
196.
Eli L. Comparison of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry. 2007;2004
197.
Eli L. Double-blind long-term study comparing the efficacy and safety of olanzapine versus haloperidol in patients with schizophrenia previously stabilized with conventional antipsychotic treatment. http://www​.clinicaltrials.gov/2010.
198.
Eli L. HGBQ: olanzapine versus haloperidol in partial responder schizophrenic patients. Data on file 2001. 2001.
199.
Eli L. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. http:​//wwwclinicalstudyresultsorg/2010. [PubMed: 10474283]
200.
Eli L. Placebo- and haloperidol-controlled double-blind trial of olanzapine in patients with manic or mixed episode of bipolar I disorder. Controlled-Trials. 2000:2006.
201.
El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Br J Psychiatry. 2006;189:102–8. [systematic review] [PubMed: 16880478]
202.
El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006;(2) [PubMed: 16625607]
203.
Ely EW. Delirium in the ICU: a prospective, randomized, trial of placebo vs haloperidol vs ziprasidone. Clin Trials. 2004;2004
204.
Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378–86. [PubMed: 19167596]
205.
Emsley R, Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2004;7(2):219–38. [PubMed: 15043765]
206.
Emsley R. Risk for akathisia in patients with recent onset schizophrenia treated with risperidone and haloperidol and its association with sucidality. Schizophr Res. 2004;(1):183.
207.
Emsley R. Risperidone in the treatment of first-episode patients with schizophreniform disorder: a double-blind multicenter study. 8th European College of Neuropsychopharmacology Congress; 1995.
208.
Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. Eur Neuropsychopharmacol. 2001;(3):264.
209.
Essali A, Al-Haj HN, Li C, et al. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;2009(1) [PubMed: 19160174]
210.
Essock SM, Frisman LK, Covell NH, et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Archives of General Psychiatry. 2000;57(10):987–94. [PubMed: 11015817]
211.
Fagiolini A, Goracci A. The long term maximising potential for rehabilitation in patients with schizophrenia. Eur Neuropsychopharmacol. 2007;17(Suppl2):S123–S129. [PubMed: 17336767]
212.
Farooq S, Sherin A. Interventions for psychotic symptoms concomitant with epilepsy. Cochrane Database Syst Rev. 2011;(4) [Systematic Review] 2011;(4) [PubMed: 18843704]
213.
Fenton M, Rathbone J, Reilly J, et al. Thioridazine for schizophrenia. Cochrane Database Syst Rev. 2007;(3) [PubMed: 17636691]
214.
Fischer-Barnicol D, Koch H, Lanquillon S, et al. The relevance of doses for comparing haloperidol, risperidone and olanzapine. Eur Psychiatry. 2010;25(Suppl 1):992.
215.
Fleischhacker W, Kahn R, Karayal O, et al. Eufest: the moderating impact of metabolic co-morbidities on treatment outcomes in first-episode schizophrenia. Eur Neuropsychopharmacol. 2009:S529–S530.
216.
Fleischhacker WW, Keet IP, Kahn RS, et al. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78(2–3):147–56. [PubMed: 16055308]
217.
Fleischhacker WW, Linz CG, Hurst BC. Ici 204636 (‘Seroquel’): a putative new atypical antipsychotic: results from phase iii trials conference proceeding. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia; 2000.
218.
Fogelson DL, Sternbach H, Payne D. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1997;17(6):492–4. [PubMed: 9408817]
219.
Fountoulakis Konstantinos N, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry. 2009;8 [PMC free article: PMC2724509] [PubMed: 19635147]
220.
Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2010;2010(4) [systematic review] [PMC free article: PMC4171386] [PubMed: 18254078]
221.
Gaebel W. One year maintenance treatment with low dose haloperidol vs risperidone in first-episode schizophrenia. http://www​.clinicaltrials.gov/2010.
222.
Gao K, Gajwani P, Elhaj O, et al. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry. 2005;66(11):1376–85. [PubMed: 16420074]
223.
Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327–40. [PubMed: 17017818]
224.
Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156(8):1270–2. [PubMed: 10450273]
225.
Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ British Medical Journal. 2000;321(7273):1371–6. [PMC free article: PMC27538] [PubMed: 11099280]
226.
George M. A double-blind randomised comparison of the efficacy and safety of short acting intramuscular olanzapine, short acting intramuscular haloperidol and intramuscular placebo in patients with schizophrenia. National Research Register. 2010
227.
Gharabawi G. Oral risperidone + lorazepam versus IM haloperidol + lorazepam in the emergency treatment of acute psychosis in schizophrenia and schizoaffective disorder. Schizophr Res. 2003;60(Suppl 1):284.
228.
Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry. 2006;163(5):938–9. [PubMed: 16648343]
229.
Gilmore JA, Kinon BJ, Zhao Improvement in quality of life and depressive symptoms in schizophrenic patients is associated with robust acute treatment response of olanzapine versus haloperidol. Schizophr Res. 2002;(3 Suppl 1):177.
230.
Gilmore JA, Kinon BJ, Zhao Rigorous criteria for treatment response differentiated efficacy of olanzapine versus haloperidol in patients with schizophrenia. Schizophr Res. 2002;(3 Suppl 1):177.
231.
Girardi P, Pompili M, Mosticoni S, et al. Intramuscular olanzapine: a critical-meta-analytic overview of some recent issues. Clin Neuropsychiatry J Treat Eval. 2006;3(4):273–81.
232.
Gismondi R. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2010. p. 2004.
233.
Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry. 1997;58(Suppl 4) [PubMed: 9265917]
234.
Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61(Suppl 4):21–6. [PubMed: 10739327]
235.
Glazer WM. Olanzapine vs haloperidol for treatment of schizophrenia. JAMA. 2004;291(9):1064–5. [PubMed: 14996766]
236.
Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol. 2002;17(2):65–8. [PubMed: 11890188]
237.
Glick ID, Lemmens P, Vester-Blokland E. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. Int Clin Psychopharmacol. 2001;16(5):265–74. [PubMed: 11552769]
238.
Glick ID, Shkedy Z, Schreiner A. Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. Int Clin Psychopharmacol. 2006;21(5):261–6. [PubMed: 16877896]
239.
Goeroecs T. Effects of aripiprazole and haloperidol on affective symptoms of schizophrenia: results from a long-term study. Proceedings of the World Psychiatric Association International Congress; 2004.
240.
Goldstein J. Efficacy and tolerability of quetiapine compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment. Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999. p. 149.
241.
Goldstein JM, Buckley P. Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000.
242.
Grainger D. Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 2010. pp. 1998–16.
243.
Green A. Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol. Schizophr Res. 2001;(2 Suppl 1):230.
244.
Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Schizophr Res. 2000;(1):189.
245.
Guilera G, Pino O, Gomez-Benito J, et al. Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials. Eur J Psychiatr. 2009;23(2):77–89.
246.
Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs. 2002;16(9):645–52. [PubMed: 12153335]
247.
Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2002;62(8):1217–51. [PubMed: 12010089]
248.
Gurovich I, Vempaty A, Lippmann S. QTc prolongation: chlorpromazine and high-dosage olanzapine. Can J Psychiatry. 2003;48(5):348. [PubMed: 12866343]
249.
Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry. 2009;195(Suppl 52):s20–s28. [PubMed: 19880913]
250.
Haffmans J. Effect of risperidone versus haloperidol on sleep in schizophrenics. Proceedings of the 11th Congress of the Association of European Psychiatrists; 2002. p. 181s.
251.
Haffmans J. The effect of risperidone versus haloperidol on sleep patterns of schizophrenic patients - results of a double-blind, randomised pilot trial. Eur Neuropsychopharmacol. 2002;(Suppl 3):S268.
252.
Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59(6):294–9. [PubMed: 9671341]
253.
Hamann J, Kissling W, Leucht S, et al. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev. 2009;2009(1) [systematic review] [PubMed: 14584012]
254.
Hamilton SH, Breier A, David S. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Eur Neuropsychopharmacol. 1998;8(Suppl 2):S228.
255.
Hamilton SH, Genduso LA, Revicki DA. Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders. Schizophr Res. 1998;29(1–2):148.
256.
Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005;73(2–3):139–45. [PubMed: 15653256]
257.
Herrera M. Double-blind study with risperidone vs haloperidol in schizophrenic patients with agitation and/or aggression P091. Proceedings of the XIII World Congress of Psychiatry; 2005.
258.
Hirsch SP. A 28-week comparison of flexible-dose ziprasidone with haloperidol in outpatients with stable schizophrenia. World Congress of Psychiatry; Hamburg. 1999.
259.
Hong W. Reduction of the positive symptoms of schizophrenia by (ICI 204,636): results from phase II and III clinical trials. 9th European College of Neuropsychopharmacology Congress; 1996.
260.
Hong X, Wang X. Agranulocytosis and neutropenia with typical and atypical neuroleptics. Am J Psychiatry. 2001;158(10):1736–7. [PubMed: 11579015]
261.
Honigfeld G, Patin J. Predictors of response to clozapine therapy. Psychopharmacology (Berl) 1989;99(Suppl 7) [PubMed: 2813666]
262.
Hosalli Prakash, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev. 2003;2009(1) [systematic review] [PubMed: 14584007]
263.
Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol. 2007;27(5):520–3. [PubMed: 17873692]
264.
Houston JP, Kaiser C. Suicideal ideation changes in olanzapine- or haloperidol-treated patients with schizophrenia. 156th Annual Meeting of the American Psychiatric Association; San Francisco CA. 2003.
265.
Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther. 2008;30(9):1565–89. [PubMed: 18840365]
266.
Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88(6):395–402. [PubMed: 7508675]
267.
Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry. 2006;67(6):897–903. [PubMed: 16848649]
268.
Hunter RH, Joy CB, Kennedy E, et al. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2) [PubMed: 12804396]
269.
Hurst BC, Link CG. A comparison of the tolerance profile of Seroquel(tm) with typical neuroleptics and placebo. Xth World Congress of Psychiatry; Madrid, Spain. 23rd–28th August 1996.
270.
Hwang TJ. IM olanzapine versus IM haloperidol plus lorazepam for acute agitation in schizophrenia. http://www​.clinicaltrials.gov/ [PubMed: 25791540]
271.
Ibrahim H. A functional MRI study of the neurocognitive effects of quetiapine compared to haloperidol in schizophrenia. Schizophr Bull. 2007;(2):371.
272.
Ibrahim H. Comparison of the neurocognitive effects of quetiapine and haloperidol in patients with schizophrenia: a functional mri study. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007. p. 24.
273.
Inada T, Beasley CM Jr, Tanaka Y, et al. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003;18(1):39–48. [PubMed: 12490774]
274.
Iskedjian M, Hux M, Remington GJ. The Canadian experience with risperidone for the treatment of schizophrenia: an overview. J Psychiatry Neurosci. 1998;23(4):229–39. [PMC free article: PMC1188939] [PubMed: 9785702]
275.
Janicak PG, Davis JM, Kasckow JW, et al. Risperidone versus haloperidol for schizoaffective disorder. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999. p. 20.
276.
Janicak PG, Glick ID, Marder SR, et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009;70(1):25–35. [PubMed: 19192472]
277.
Janicak PG, Keck P. Double-blind, randomized study of risperidone vs haloperidol for schizoaffective disorder. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999. p. 16.
278.
Janknegt R, Derijks L, Becker HE, et al. Antipsychotic agents in the treatment of schizophrenia: drug selection by means of the SOJA method. J Drug Assess. 2002;5(3):S1–S30.
279.
Janssen LP. A comparison of risperidone and haloperidol for prevention of relapse in subjects with schizophrenia and schizoaffective disorders. http://www​.clinicaltrials.gov/
280.
Janssen. Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel-group comparative study versus haloperidol. http://www​.clinicaltrials.gov/
281.
Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull. 2002;28(4):589–605. [PubMed: 12795493]
282.
Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31. [PMC free article: PMC2386457] [PubMed: 18439263]
283.
Johnson AL, Johnson DAW, Peuskens J. Peer review of ‘Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol’ Br J Psychiatry. 1995;166:727–33. [PubMed: 7545060]
284.
Johnstone BM, Obenchain RL, Edgell ET, et al. Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol. 11th European College of Neuropsychopharmacology Congress; 1998.
285.
Joint formulary committee. British National Formulary. 49th edition. 2011. Available from: URL: http://www​.bnf.org/
286.
Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry. 2001;62(Suppl 4) [PubMed: 11232747]
287.
Jones B. Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998.
288.
Kabanov SO, Mosolov SN. Cognitive functioning under treatment with risperidone and haloperidol in acute phase of schizophrenia. Schizophr Res. 2002;(3 Suppl 1):193–4.
289.
Kando JC, Shepski JC, Satterlee W, et al. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother. 1997;31(11):1325–34. [PubMed: 9391688]
290.
Kane J. Aripiprazole in treatment-resistant schizophrenia: a 6-week double- blind comparison study versus perphenazine. Schizophr Res. 2004;(1):155–6.
291.
Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019–29. [PubMed: 20008446]
292.
Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res. 2007;95(1–3):143–50. [PubMed: 17644313]
293.
Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627–43. [PubMed: 19389331]
294.
Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2:Suppl 1):29–35. [PubMed: 18334910]
295.
Kane JM, Suncao-Talbott S, Eudicone JM, et al. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res. 2008;105(1–3):208–15. [PubMed: 18790605]
296.
Kane JM, Swyzen W, Wu X, et al. Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006.
297.
Kane JM, William HCJ, Kujawa MJ, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003. p. 22.
298.
Kane JM. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. 156th Annual Meeting of the American Psychiatric Association; May 17–22; San Francisco CA. 2003.
299.
Kasper S, Tauscher J, Kufferle B, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol: a 123I-IBZM SPECT study. Psychopharmacology (Berl) 1998;136(4):367–73. [PubMed: 9600582]
300.
Keck PE, Reeves KR. The efficacy of ziprasidone in schizophrenia and schizoaffective disorder: an update. Sixth World Congress of Biological Psychiatry; Nice France. Jun 22-7, 1998.
301.
Keshavan MS, Schooler NR, Sweeney JA, et al. Research and treatment strategies in first-episode psychoses: the Pittsburgh experience. Br J Psychiatry Suppl. 1998;172(33):60–5. [PubMed: 9764128]
302.
Khan A, Schwartz K, Stern C, et al. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. J Clin Psychiatry. 2007;68(12):1828–33. [PubMed: 18162012]
303.
Khanna S, Rajadhyaksha Ziprasidone versus chlorpromazine in treatment-refractory schizophrenia. Schizophr Res. 2003:290–1.
304.
Kim JG, Cho DH, Lee SJ, et al. The comparison of efficacy between aripiprazole and haloperidol in treatment of chronic schizophrenia and schizoaffective disorder: results for 16-week clinical study. Eur Neuropsychopharmacol. 2006;(Suppl 4):S417.
305.
Kim JH, Byun HJ. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther. 2007;32(5):461–7. [PubMed: 17875112]
306.
Kinon BJ, Basson MS, Tollefson GD. Gender-specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998. pp. 1998–13.
307.
Kinon BJ, Chen L, Stauffer VL, et al. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol. 2010;30(3):286–9. [PubMed: 20473064]
308.
Kinon BJ, scher-Svanum H, Adams DH, et al. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J Clin Psychopharmacol. 2008;28(5):544–9. [PubMed: 18794651]
309.
Kleinberg DL, Davis JM, de CR, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57–61. [PubMed: 9934944]
310.
Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics. 2008;26(4):341–58. [PubMed: 18370568]
311.
Ko G. Status report: ziprasidone conference abstract. Schizophrenia Research (The Vth International Congress on Schizophrenia Research); Wormsprings, VA USA. 1995.
312.
Kopala L. EPS in recent onset schizophrenia: a comparison of risperidone and haloperidol. Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003. p. 24.
313.
Kopala L. Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Eur Neuropsychopharmacol. 2003;(4):S338.
314.
Kopala L. Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Schizophr Res. 2004;(1):187.
315.
Korea HGFH. HGFH_Korea. Cochrane Schiphrenia Group. 1989
316.
Kostakoglu E, Alptekin Olanzapine vs. chlorpromazine- 6 weeks treatment of acute schizophrenia errata. Eur Neuropsychopharmacol. 2001;(Suppl 3):S369.
317.
Kostic D. Maintenance of response in chronic schizophrenia: effects of aripiprazole and haloperidol on affective symptoms. Schizophr Bull. 2005;31(2):492.
318.
Krakowski MI, Czobor P. Clozapine, olanzapine, and haloperidol treatment of violent patients with schizophrenia. 158th Annual Meeting of the American Psychiatric Association; 2005.
319.
Kudo Y. Clinical trial of quetiapine in schizophrenia - efficacy and tolerability of quetiapine: a comparative double-blind study with masopramine in schizophrenic patients. Ann Meet World Psychiatr Assoc. 1999
320.
Kujawa M, Saha AR, Ingenito GG. Aripiprazole for long-term maintenance treatment of schizophrenia. XXIII Collegium Internationale Neuro-Psychopharmacologium (CINP) Congress; Montreal. 2002. [poster]
321.
Kunz M. Olanzapine vs haloperidol for treatment of schizophrenia. JAMA. 2004;291(9):1065–6. [PubMed: 14996768]
322.
Lahti AC, Holcomb HH, Weiler MA, et al. Changes rcbf after acute challenge with haloperidol and olanzapine in patients with schizophrenia conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe New Mexico USA. 1999. pp. 17–21.
323.
Lal S, Lal S. Chlorpromazine-induced cutaneous pigmentation: effect of replacement with clozapine. J Psychiatry Neurosci. 2000;25(3):281. [PMC free article: PMC1407720] [PubMed: 10863889]
324.
Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(5):702–6. [PubMed: 15163259]
325.
Langbein K, Nenadic I, Rzanny R, et al. Differential effects of first- and second-generation antipsychotics on energy metabolism in frontal and temporal cortex of first-episode schizophrenia patients. Eur Arch Psychiatry Clin Neurosci. 2009:S83.
326.
Lauriello J. Longitudinal assessment of brain chemistry early in schizophrenia: a randomized controlled trial of quetiapine and haloperidol. Schizophr Bull. 2005;31(2):444.
327.
Lee JN, Yang BH, Nam CW. The influences of risperidone and clozapine on body weight and glucose level in patients with chronic schizophrenia: comparison with haloperidol. Eur Neuropsychopharmacol. 2005;(Suppl 3):S457.
328.
Lee M. Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry; 2001. p. 2001.
329.
Lemieux AA, Goldman-Levine JD, Goren JL. Aripiprazole: an antipsychotic with a novel mechanism of action. J Pharm Technol. 2003;19(6):365–72.
330.
Lemmens P, Brecher M, Van BB. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999;99(3):160–70. [PubMed: 10100910]
331.
Lemmens P. Tolerability and cardiovascular safety of risperidone. Sixth World Congress of Biological Psychiatry; Nice, France. Jun 22-7, 1998.
332.
Leo R, Razzini C, Di LG, et al. Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol. J Clin Psychiatry. 2008;69(2):327–8. [PubMed: 18363460]
333.
Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. The American Journal of Psychiatry. 2003;160(7):1209–22. [PubMed: 12832232]
334.
Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352–60. [PubMed: 17388703]
335.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. [PubMed: 19058842]
336.
Leucht S, Engel RR, Bauml J, et al. Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophr Bull. 2007;33(1):183–91. [PMC free article: PMC2632292] [PubMed: 16905632]
337.
Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68. [PubMed: 9988841]
338.
Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361(9369):1581–9. [PubMed: 12747876]
339.
Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005;2009(1) [systematic review]
340.
Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Rockv) 2006;10(17):1–94. [PubMed: 16707074]
341.
Licht RW, Bech P. How to manage mania not responding to a first-step 2 weeks treatment with quetiapine: a report from a prematurely discontinued randomised clinical trial. Acta Psychiatr Scand. 2009;120(4):334–5. [PubMed: 19689481]
342.
Licht RW. Typical and atypical antipsychotics in bipolar disorder. Acta Neuropsychiatr. 2000;12(3):115–9. [PubMed: 26975267]
343.
Lieberman J. Olanzapine and haloperidol treatment of first epiode schizophrenia and schizoaffective disorder: 12 week outcome of a two year randomized double blind trial. Proceedings of the 2nd International Conference on Early Psychosis; 2000.
344.
Lieberman J. Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol treatment in a 3-year double-blind extension study. Neuropsychopharmacology. 2005;(Suppl 1):S197–S198.
345.
Lieberman JA, Stroup TS, Mc Evoy JP, et al. Newer antipsychotics similar to older agents. J Fam Pract. 2005;54(12):1026. [PubMed: 16370079]
346.
Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol: correction. The American Journal of Psychiatry. 2003;160(10):1901. [PubMed: 12900300]
347.
Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11(1):25–32. [PubMed: 11226809]
348.
Lima MS, de Jesus Mari Quality of life of patients with schizophrenia: a randomized, naturalistic, controlled trial comparing olanzapine with typical antipsychotics in Brazil. 156th Annual Meeting of the American Psychiatric Association; San Francisco, USA. 2003.
349.
Lin CH, Kuo CC, Chou LS, et al. A randomized, double-blind, comparison of risperidone versus risperidone plus haloperidol treatment in schizophrenia. Eur Neuropsychopharmacol. 2009;19(Suppl3):S256.
350.
Lindborg SR, Beasley CM, Alaka K, et al. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003;119(1–2):113–23. [PubMed: 12860365]
351.
Lindenmayer J. A randomized, double-blind study of olanzapine vs haloperidol in the treatment of primary negative symptoms in schizophrenia. Schizophr Bull. 2005;31(2):493–4.
352.
Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8):1084–9. [PubMed: 15323593]
353.
Lindenmayer JP. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993.
354.
Lindner LM, Marasciulo AC, Farias MR, et al. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009;43(Suppl 9) [PubMed: 19669066]
355.
Lingjaerde O. Risperidone versus perphenazine in schizophrenia: a double-blind multicentre study. Clin Neuropharmacol. 1992;(Suppl 1. Pt B):375b.
356.
Lipkovich I, Baron D, Houston J, et al. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol. 2005;25(4):381–6. [PubMed: 16012284]
357.
Litman RE, Hommer DW, Radant A, et al. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophr Res. 1994;12(2):107–20. [PubMed: 8043521]
358.
Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21. [PMC free article: PMC1327673] [PubMed: 16375765]
359.
Loebel A. Predictors of long-term outcome in schizophrenia: a double-blind, 196-week study of ziprasidone and haloperidol. Schizophr Bull. 2007;(2):442.
360.
Loza N. Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol. 1999;(Suppl 5):S291.
361.
Lu Y. Olanzapine in the treatment of schizoaffective disorder. 9th European College of Neuropsychopharmacology Congress; 1996.
362.
Lysaker PH. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks. Evid Based Ment Health. 2006;(3):71. [PubMed: 16868190]
363.
Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust NZ J Psychiatry. 2005;39(1–2):44–54. [PubMed: 15660705]
364.
Mahmoud RA, Engelhart LM. Risperidone versus conventional antipsychotics in usual care: a prospective randomised effectiveness trial of outcomes for patients with schizophrenia and schizoaffective disorder. 1998.
365.
Mahmoud RA, Engelhart MA. Risperidone vs conventional antipsychotics in ususl care: a prospective randomized effectiveness trial of outcomes for patients with schizophrenia and schizoaffective disorder. 21st Collegium internationale neuro-psychopharmaclogicum congress; 1998.
366.
Mak KY, Ng S, Wong MC, et al. A cost-analysis of risperidone in the treatment of chronic schizophrenia with predominating negative symptoms in Hong Kong. Hong Kong J Psychiatr. 2000;10(3):14–44.
367.
Malhotra A. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Neuropsychopharmacology. 2005;(Suppl 1):S199–S200.
368.
Malyarov SD. Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol. Eur Neuropsychopharmacol. 1999:S269.
369.
Malyarov SD. Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol. 1999. p. 296.
370.
Malykhin N. Comparative efficacy of risperidone, clozapine and haloperidol in the treatment of schizoaffective disorders with manic symptoms. Eur Neuropsychopharmacol. 2003;(4):S304.
371.
Marazuela R, Rubio-Terres C, Giner J, et al. Pharmacoeconomic analysis of the treatment of schizophrenia with quetiapine, olanzapine, risperidone or haloperidol in Spain. J Med Econ. 2006;9(101–119):101–19.
372.
Marder S. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clin Res Rep RIS-INT-3. 1991:1991.
373.
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538–46. [PubMed: 9448657]
374.
Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2–3):123–36. [PubMed: 12729864]
375.
Marder SR, Wirshing WC, Glynn S, et al. Risperidone and haloperidol in maintenance treatment: Interactions with psychosocial treatments. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe New Mexico USA. 1999. pp. 17–21.
376.
Marder SR. Risperidone: efficacy. J Clin Psychiatr Monogr. 1994;12(2):49–52.
377.
Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother. 2010;44(5):863–70. [PubMed: 20388862]
378.
Martin JL, Perez V, Sacristan M, et al. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry. 2006;21(1):11–20. [PubMed: 16380237]
379.
Martinez R. Risperidone versus haloperidol for prevention of relapse in schizohrenia and schizoaffective disorders. Schizophr Res. 1999:1–3.
380.
Mattes JA. Risperidone: how good is the evidence for efficacy? Schizophr Bull. 1997;23(1):155–61. [PubMed: 9050121]
381.
Mattingly G, Hochfeld M, Meng X. Response rates with iloperidone among patients with schizophrenia: pooled date from 2 phase iii clinical trials. November 18–21, 2010; Orlando, Florida. United States Psychiatric and Mental Health Congress.2010.
382.
McEvoy J. Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia. Schizophr Res. 2003;60(1):313.
383.
McGurk SR, Green MF, Wirshing WC, et al. The effects of risperidone vs. haloperidol on spatial working memory in treatment-resistant schizophrenia. Biol Psychiatry. 1996;39(1):571.
384.
McGurk SR, Green MF, Wirshing WC, et al. The effects of risperidone versus haloperidol on frontal lobe functioning in treatment-resistant schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997. pp. 1997–22.
385.
McGurk SR, Green MF, Wirshing WC, et al. The effects of risperidone versus haloperidol on frontal lobe functioning in treatment-resistant schizophrenia. 150th Annual Meeting of the American Psychiatric Association; 1998.
386.
McQuade R. Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. Eur Neuropsychopharmacol. 2003;(4):S326.
387.
McQuade R. Intramuscular aripiprazole in acute schizophrenia: a double-blind, placebo-controlled comparison with IM haloperidol. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006. p. 10.
388.
Meibach RC. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 2000;55(7):1069. [PubMed: 11061283]
389.
Meltzer D. Remission in schizophrenia: a comparison of the cost-effectiveness of 2 dose regimens of ziprasidone versus haloperidol treatment in a 3-year double-blind extension study. Schizophr Bull. 2007;(2):487.
390.
Meltzer H, Cohen M, Snow-Adami L, et al. Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia. Eur Neuropsychopharmacol. 2009;19(Suppl 3):S536–S537.
391.
Meltzer HY, Kujawa MJ, Carson JWH, et al. Aripiprazole and perphenazine in severe treatment-resistant schizophrenia. Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004. p. 6.
392.
Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry. 1992;17:46–53. [PubMed: 1418889]
393.
Mendelowitz AJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry. 2004;16(3):145–54. [PubMed: 15517847]
394.
Messotten F. Risperidone versus haloperidol in the treatment of chronic psychotic patients: a multi center double-blind study. Cochrane Collaboration. 1991
395.
Meyer JM, Davis VG, McEvoy JP, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res. 2008;103(1–3):104–9. [PMC free article: PMC2583138] [PubMed: 18534821]
396.
Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;(1):9–18. [PubMed: 16125372]
397.
Miller DD, Eudicone JM, Pikalov A, et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry. 2007;68(12):1901–6. [PubMed: 18162021]
398.
Miller DD, O’Leary DS, Andreasen NC. Comparison of the effect of haloperidol and risperidone on regional cerebral blood flow in schizophrenia conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); 1999. p. 228.
399.
Miller DD, O’Leary DS, Andreasen NC. Differences in the effect of risperidone and haloperidol on RCBF in patients with schizophrenia performing a practiced memory task. Schizophr Res. 2001;(1,2):181–2.
400.
Miller DD, Ziebell S, Nopoulos Risperidone versus haloperidol in a prospective longitudinal follow-up of recent-onset schizophrenia schizophrenia. Schizophrenia Research (Special Issue) - The VIth International Congress on Schizophrenia Research); Colorado Springs, Colorado, USA. 1997.
401.
Mimica N. Olanzapine compared to fluphenazine in the treatment of schizophrenia conference presentation. Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia; 1998.
402.
Modell SJ. Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotics. Eur Neuropsychopharmacol. 2004;(Suppl 3):S265.
403.
Moller HJ. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand Suppl. 2000;400:17–22. [PubMed: 10823307]
404.
Moller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17(11):793–823. [PubMed: 12921492]
405.
Moncrieff J. Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161–6. [PubMed: 12893670]
406.
Montero I, Talavera M, Ruiz I. Clinical trials with a new atypical antipsychotic (aripiprazole): Gender specific information analysis. Women Health. 2008;47(4):39–51. [PubMed: 18843939]
407.
Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials. 2004;25(6):598–612. [PubMed: 15588746]
408.
Mullen B, Brar JS, Vagnucci AH, et al. Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. Schizophr Res. 2001;48(1):155–8. [PubMed: 11345946]
409.
Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol. 1992;15(Suppl 91A) [PubMed: 1379882]
410.
Murasaki M. Clinical evaluation of quetiapine in schizophrenia: efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Proceedings of the 11th World Congress of Psychiatry; 1999. p. 11.
411.
Murasaki M. Risperidone in the treatment of schizophrenia: a double-blind comparison with haloperidol. Eur Neuropsychopharmacol. 1995;5(Supplement 1):350.
412.
Murasaki M. Risperidone in the treatment of schizophrenia: a double-blind comparison with haloperidol. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995-Oct.1995.
413.
Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88(1–3):5–25. [PubMed: 16930948]
414.
Myers J. The long-term benefit of risperidone versus haloperidol for affective symptoms in schizophrenia and schizoaffective disorder. Schizophr Res. 2001;(1,2):240.
415.
Myers JE, Mahmoud RA, Keith SJ, et al. Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder. 154th Annual Meeting of the American Psychiatric Association; 2001.
416.
Nagao M. Quantitative electroencephalography in schizophrenia: therapeutic effects of haloperidol and risperidone. 11th European College of Neuropsychopharmacology Congress; 1998.
417.
Namjoshi M. Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a US random study. Int J Neuropsychopharmacol. 2002;(Suppl 1):S127.
418.
Namjoshi M. Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial. Schizophr Res. 2003;60(Suppl 1):296.
419.
Namjoshi M. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol. 2002;(Suppl 3):S315.
420.
Namjoshi M. Olanzapine versus haloperidol: improvements in quality of life and compliance with treatment in patients with bipolar disorder. 154th Annual Meeting of the American Psychiatric Association; 2001.
421.
Namjoshi Madhav, Shi Lizheng, Zhang Fan, et al. Olanzapine versus haloperidol: improvements in quality of life and compliance with treatment in patients with bipolar disorder. 155th Annual Meeting of the American Psychiatric Association; 2002.
422.
Nasrallah HA, Brecher M, Paulsson B. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disord. 2006;8(5:Pt 1):74. [PubMed: 17042884]
423.
Nasrallah HA, Rennie P. Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol. Eur Neuropsychopharmacol. 2001;(3):262.
424.
Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry. 2006;18(1):57–62. [PubMed: 16517454]
425.
Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr. 2006;11(Suppl 7):7–9. [PubMed: 16816798]
426.
Naukkarinen H. Olanzapine and perphenazine in schizophrenia. Schizophr Res. 2000;(1):190.
427.
Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997;58(Suppl 9) [PubMed: 9265916]
428.
Nguyen LN, Guthrie SK. Risperidone treatment of bipolar mania. Ann Pharmacother. 2006;40(4):674–82. [PubMed: 16569811]
429.
Nightengale BS, Garrett L, Waugh S, et al. Health economics: economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am J Managed Care. 1998;4(3):360–6. [PubMed: 10178498]
430.
O’Connor R. A 28-week comparison of flexible-dose ziprasidone with haloperidol in outpatients with stable schizophrenia: risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: a long-term, double-blind comparison. Proceedings of the 51st Institute on Psychiatric Services; Nov, 1999.
431.
Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol. 2001;8(4):199–206. [PubMed: 11743592]
432.
Oh PI, Lanctot KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4(137–156):137–56.
433.
Olanzapine for injection: new formulation. Prescrire Int. 2004;13(71):92–3. [PubMed: 15233144]
434.
Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;66(3):331–8. [PubMed: 15766299]
435.
Oren D. Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophr Bull. 2005;31(2):499.
436.
Oren DA, Marcus RN, Manos Non-inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder. Schizophr Bull. 2007;33(2):451.
437.
Organon. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using haloperidol positive control in subjects with an acute exacerbation of schizophrenia. http://www​.clinicaltrials.gov/2010.
438.
Palmer CS, Brunner E, Ruiz-Flores LG, et al. A cost-effectiveness clinical decision analysis model for treatment of schizophrenia. Arch Med Res. 2002;33(6):572–80. [PubMed: 12505105]
439.
Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin. 2006;22(2):241–55. [PubMed: 16466596]
440.
Parsons B, Allison DB, Loebel A, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1–3):103–10. [PubMed: 19321312]
441.
Pathiraja AP, Diamond BI, Borison RL, et al. Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs conference abstract. Schizophrenia Research (The Vth International Congress on Schizophrenia Research); Wormsprings, VA USA. 1995. p. 160.
442.
Pecenak J. Relapse prevention in schizophrenia: Evidence from long-term, randomized, double-blind clinical trials. Neuroendocrinol Lett. 2007;28(Suppl 1):49–70. [PubMed: 17262007]
443.
Pelayo-Teran JM, Perez-Iglesias R, Mata I, et al. Early response to antipsychotics as a marker of treatment response of psychosis. Schizophr Res. 2010;180
444.
Peralta V, Campos MS, de Jalon EG, et al. DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res. 2010;118(1–3):168–75. [PubMed: 20071147]
445.
Perez R. Efficacy and safety of olanzapine, risperidone and haloperidol in acute treatment of patients with first episode psychosis. Schizophr Res. 2003;9
446.
Peters P. A randomized, double blind, multi-center study to assess the antipsychotic and motor effects of acp-103 when administered in combination with haloperidol or risperidone to schizophrenic subjects. http://www​.clinicaltrials.gov/
447.
Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: phase 2 clinical trial result. 10th European College of Neuropsychopharmacology Congress; 1997.
448.
Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002;12(4):305–10. [PubMed: 12126869]
449.
Peuskens J, Van BB, De SC, et al. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol. 2000;15(6):343–9. [PubMed: 11110010]
450.
Peuskens J. Risperidone in the treatment of chronic schizophrenic patients: an international double blind parallel group comparative study versus haloperidol. Clin Report. 1992;1992
451.
Pfizer. Ziprasidone intramuscular/oral versus haloperidol intramuscular/oral in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: a six week open administration study with blinded assessments. http:​//wwwclinicalstudyresultsorg/2010.
452.
Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Archives of General Psychiatry. 1992;49(5):345–53. [PubMed: 1375019]
453.
Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Expert Opin Pharmacother. 2006;7(7):929–40. [PubMed: 16634715]
454.
Pivac N. The effects of olanzapine or fluphenazine on peripheral biochemical markers in schizophrenic patients. Int J Neuropsychopharmacol. 2002;(Suppl 1):S184.
455.
Plesnicar BK, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol. 2006;20(6):829–33. [PubMed: 16478753]
456.
Pogarell O, Juckel G, Mulert C, et al. EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol. Pharmacopsychiatry. 2004;37(6):304–5. [PubMed: 15551199]
457.
Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry. 2006;163(12):2047–56. [PubMed: 17151153]
458.
Postgraduate Medicine. Antipsychotics and diabetes: case reports and cohort studies. Postgrad Med. 2003;114(Suppl 6):59–71. [PubMed: 19667653]
459.
Potkin SG, Gutierrez R. 150th Annual Meeting of the American Psychiatric Association; 1997 May 17–22nd; San Diego, California, USA. 1997.
460.
Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(Suppl 1):2–11. [PubMed: 18334911]
461.
Potkin SG. Efficacy and safety of once-daily dosing with risperidone in patients with schizophrenia. 1997.
462.
Purdon SE. Canadian CaOSG. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol. Schizophr Res. 1998;(1,2):152–3.
463.
Purdon SE, Jones B. A multicentre comparison of olanzapine, risperidone, and haloperidol on working memory, new learning, and delayed recall of verbal and nonverbal materials in early-phase schizophrenia over a 12-month prospective double-blind clinical trial. Schizophr Res. 1999;(1–3):150.
464.
Purdon SE, Jones BDW, Stip EL. Olanzapine versus haloperidol versus risperidone in early illness schizophrenia. Data on File. 2001. pp. 39–45.
465.
Purdon SE, Malla A. Neuropsychological change in schizophrenia after 6 months of double blind treatment with quetiapine or haloperidol. Schizophr Res. 2000;(1):205–6.
466.
Rabinowitz J, Levine SZ, Barkai O, et al. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35(4):775–88. [PMC free article: PMC2696366] [PubMed: 18303093]
467.
Ramey T. 12-week, double-blind, placebo-controlled study of ziprasidone vs haloperidol for efficacy and maintained treatment effect in acute bipolar mania. Neuropsychopharmacology. 2004:S203.
468.
Rappard F. Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study. Eur Neuropsychopharmacol. 2006;(Suppl 4):S390.
469.
Rappard F. Remission in schizophrenia: a comparison of two dose regimens of ziprasidone versus haloperidol treatment in a three-year double blind extension study. Proceedings of the 19th European College of Neuropsychopharmacology Congress; 2006. p. 20.
470.
Rasmussen M. The impact on long-term outcome of early intervention with risperidone or haloperidol in first episode psychosis: characteristics at baseline conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe New Mexico USA. 1999. pp. 17–21.
471.
Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev. 2007;2009(1) [systematic review]
472.
Rendell JM, Gijsman HJ, Bauer MS, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev. 2006;2009(1) [systematic review] [PubMed: 16437472]
473.
Rendell JM, Gijsman HJ, Keck PK, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev. 2009;2009(1) [systematic review] [PubMed: 12918000]
474.
Reveley M. Seroquel outcome study (SOS): a multicentre double-blind randomised trial to compare the effects of seroquel and chlorpromazine on treatment outcome of schizophrenic patients. National Research Register. 2010
475.
Revicki D. Effect of olanzapine on deficit syndrome symptoms in chronic schizophrenia. 8th European College of Neuropsychopharmacology Congress; 1995.
476.
Revicki D. Olanzapine versus haloperidol therapy for chronic schizophrenia: impact on deficit syndrome. Eur Neuropsychopharmacol. 1995;5(Suppl 1):347.
477.
Revicki D. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and other psychotic disorders: results of an international randomized clinical trial. Qual Life Res. 1996 [PubMed: 10474283]
478.
Revicki D. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996. pp. 1996–9.
479.
Richardson CM, Kelly DL, old JM, et al. Risperidone vs quetiapine vs fluphenazine in treatment-resistant schizophrenia: neuropsychological outcome. Schizophr Bull. 2005;31(2):501–2.
480.
Rimon R. Olanzapine versus perphenazine in the treatment of schizophrenia: a double-blind study. Schizophr Res. 2004;(1):164–5.
481.
Rodova A, Svestka J, Nahunek K, et al. A blind comparison of clozapine and perphenazine in schizophrenics. Act Nerv Super (Praha) 1973;15(2):94–5. [PubMed: 4752682]
482.
Rosenheck R, Cramer J, Allan E, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Archives of General Psychiatry. 1999;56(6):565–72. [PubMed: 10359474]
483.
Rosenheck R, Cramer J, Xu W, et al. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia on Clozapine in Refractory Schizophrenia. Health Serv Res. 1998;33(5:Pt 1):1261. [PMC free article: PMC1070315] [PubMed: 9865219]
484.
Rosenheck R, Doyle J, Leslie D, et al. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull. 2003;29(1):81–93. [PubMed: 12908663]
485.
Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080–9. [PubMed: 17151158]
486.
Rosenheck RA. Aripiprazole and perphenazine: no difference. J Clin Psychiatry. 2000;68(11):1812–3. [PubMed: 18052580]
487.
Rosenheck RA. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatric Services. 2005;56(1):85–92. [PubMed: 15637198]
488.
Sa AR, Hounie AG, Sampaio AS, et al. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry. 2009;50(5):437–42. [PubMed: 19683614]
489.
Sanchez R. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. Schizophr Bull. 2005;31(2):502.
490.
Sanger T. A controlled study on the course of primary and secondary negative symptoms conference abstract. 150th Annual Meeting of the American Psychiatric Association; 1997.
491.
Sanger TM, Lieberman JA, Tohen Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia; 1998. p. 151.
492.
Satterlee W. Olanzapine, a new “atypical” antipsychotic. Schizophrenia Research (The Vth International Congress on Schizophrenia Research); Wormsprings, VA USA. 1995.
493.
Sauriol L, Laporta M, Edwardes MD, et al. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther. 2001;23(6):942–56. [PubMed: 11440294]
494.
Schausberger B. Impact of olanzapine versus fluphenazine on patient’s drug acceptance during acute treatment of schizophrenia. Eur Neuropsychopharmacol. 1992
495.
Schennach-Wolff R, Jager M, Mayr A, et al. Early response and its predictive validity within a randomised double-blind 1 year follow-up trial. Eur Arch Psychiatry Clin Neurosci. 2009:S57.
496.
Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Archives of General Psychiatry. 2007;64(4):442–55. [PubMed: 17404121]
497.
Schooler N. Reduced relapse rates in recent onset schizophrenia patients treated with risperidone vs. haloperidol. Eur Neuropsychopharmacol. 2003;(4):S337.
498.
Schooler NN. The efficacy and safety of conventional and atypical antipsychotics in first-episode schizophrenia: a review of the literature. Clin Schizophr Relat Psychoses. 2007;1(1):27–42.
499.
Schulz S. Efficacy of quetiapine compared with haloperidol and placebo in the short-term treatment of acute schizophrenia. Eur Neuropsychopharmacol. 2000;(Suppl 3):302–3.
500.
Schulz S. Efficacy of quetiapine versus haloperidol and placebo in the short-term treatment of acute schizophrenia. 153rd Annual Meeting of the American Psychiatric Association; Chicago, Illionois, USA. 2000.
501.
Schulz SC, Thomson R, Brecher M. The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res. 2003;62(1–2):1–12. [PubMed: 12765737]
502.
Scott LJ. Iloperidone: in schizophrenia. CNS Drugs. 2009;23(10):867–80. [PubMed: 19739696]
503.
Sharma T. A multi-centre, double-blind, randomised trial to compare the effects of “seroquel” and haloperidol in schizophrenic patients with a history of partial response to antipsychotic treatment. National Research Register. 2001
504.
Sherwood M, Thornton AE, Honer WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int J Neuropsychopharmacol. 2006;9(3):357–66. [PubMed: 16316478]
505.
Shi L. Olanzapine versus haloperidol as initial treatment in acute mania: prospective comparison of work functional outcomes. Int J Neuropsychopharmacol. 2002;(Suppl 1):108.
506.
Shi Lizheng, Namjoshi Madhav, Mauricio Tohen. Olanzapine versus haloperidol: a prospective comparison of clinical and humanistic outcomes in bipolar disorder. 155th Annual Meeting of the American Psychiatric Association; 2002.
507.
Shim JC, Choe BM, Kim JG, et al. Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):400–1. [PubMed: 17632229]
508.
Si T. Multicenter, open-label, randomised, haloperidol-controlled study to evaluate seroquel as mono-therapy in the treatment of agitated symptoms in the patients with acute episode of schizophrenia. 2010. http:​//wwwclinicaltrialsgov.
509.
Silveira da Mota Neto J, Soares B, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database Syst Rev. 2002;2009(1) [systematic review]
510.
Sim K, Su A, Leong JY, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry. 2004;37(4):175–9. [PubMed: 15467975]
511.
Singh OP, Chakraborty I. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Pscychiatry. 2008;(3):171–6. [PMC free article: PMC2738368] [PubMed: 19742187]
512.
Siu C. Missing data and dropouts in a long-term, double-blind schizophrenia study comparing ziprasidone and haloperidol. Int J Neuropsychopharmacol. 2008;(Suppl 1):161.
513.
Skelton JA, Pepe MM, Pineo TS. How much better is clozapine? A meta-analytic review and critical appraisal. Exp Clin Psychopharmacol. 1995;3(3):270–9.
514.
Smelson DA, Ziedonis D. A double blind study comparing olanzapine to haloperidol for reducing cue-elicited craving in individuals with schizophrenia and cocaine dependence. Schizophr Res. 2003;60(Suppl 1):S303.
515.
Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406–11. [PubMed: 18515889]
516.
Soares B, Silva de Lima M. Penfluridol for schizophrenia. Cochrane Database Syst Rev. 2006;2010(5) [systematic review]
517.
Soares-Weiser K, Bravo VY, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess. 2007;11(39):iii–iiv. [PubMed: 17903393]
518.
Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006;2009(1) [systematic review]
519.
Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol. 2008;61(5):455–63. [PubMed: 18394538]
520.
Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol. 1997;11(1):65–71. [PubMed: 9097896]
521.
Soumerai SB, Law MR, Rosenheck Cost-effectiveness of schizophrenia pharmacotherapy. Am J Psychiatry. 2007;(4):678–80. [PubMed: 17403984]
522.
Soyka M, Dittert S, Schafer M, et al. Psychomotor performance under neuroleptic treatment in schizophrenia: a comparative study of haloperidol and risperidone. Z Neuropsychologie. 2001;12(1):49–53.
523.
Soyka M, Winter C, Kagerer S, et al. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J Psychiatr Res. 2005;39(1):101–8. [PubMed: 15504428]
524.
Spannheimer A, Reitberger U, Clouth J, et al. Length of hospital stay and associated costs for olanzapine vs. haloperidol in the treatment of schizophrenia relapse in Germany. Eur J Health Econ. 2003;4(2):85–9. [PubMed: 15609173]
525.
Spivak M, Adams B, Crockford D. Atypical neuroleptic malignant syndrome with clozapine and subsequent haloperidol treatment. Can J Psychiatry. 2003;48(1):66. [PubMed: 12635570]
526.
Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother. 2004;38(2):313–9. [PubMed: 14742771]
527.
Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(2) [PubMed: 15106155]
528.
Stahl S, Kainer J, Hochfeld M, Baroldi P. The metabolic profile of iloperidone: summary of phase ii and iii schizophrenia trials. Austin, TX: American College of Clinical Pharmacy; Oct, 17–20, 2010. 2010.
529.
Stahl SM, Malla A, Newcomer JW, et al. Symptomatic and functional recovery index for negative symptoms in a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-yaer double-blind extension trial. Schizophr Res. 2010;117(2–3):502. [PubMed: 20571437]
530.
Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32(Suppl 1):S3–S20. [PubMed: 20152550]
531.
Stock EA. Long-term effects of aripiprazole and haloperidol on affective symptoms of schizophrenia. Schizophr Res. 2004;(1):158–9.
532.
Suh GH, Greenspan AJ, Choi SK. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2007;22(5):494–5. [PubMed: 17471597]
533.
Sundararajan V, Jainer AK. A mood stabilizer with risperidone or haloperidol for mania. Am J Psychiatry. 2004;161(11):2139–40. [PubMed: 15514433]
534.
Suttajit S, Srisurapanont M, Maneeton B, et al. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2009;2009(1) [protocol] [PubMed: 23728667]
535.
Suzana STTG, Olivera ZOZ, Gordana NGN, et al. Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia. Eur Neuropsychopharmacol. 2009:S532.
536.
Svestka J. Double-blind clinical comparison of riperidon and haloperidol in acute schizophrenic and schizoaffective psychoses. Act Nerv Super (Praha) 1990;(3):237–8.
537.
Swift RH, Harrigan EP, van Kammen DP. A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible-dose, IM haloperidol. 151st American Psychiatric Association Meeting; 1998.
538.
Swift RH, Harrigan EP, van Kammen DP. A comparison of intramuscular ziprasidone with im haloperidol conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe, New Mexico, USA. 1999. pp. 17–21. 1999.
539.
Szafranski T. Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine. Eur Neuropsychopharmacol. 1999
540.
Talbott SB. Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine-analyses of the first 12 weeks of three double-blind, long-term trials. Proceedings of the 11th International Congress on Schizophrenia Research; Apr, 2007.
541.
Tamura RN, Tollefson GD, Dellva MA, et al. What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?. Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia); 1998.
542.
Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research. 2008;100(1–3):20–38. [PubMed: 18243663]
543.
Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res. 2005;79(2–3):145–55. [PubMed: 16139989]
544.
Taneli B. Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia. Eur Neuropsychopharmacol. 2003;(4):S287.
545.
Tapp A. Double-blind comparison of quetiapine and haloperidol on cognitive functioning in patients with schizophrenia. Schizophr Bull. 2005;31(2):379.
546.
Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evid Based Ment Health. 2007;(3):76. [PubMed: 17652558]
547.
Thornton AE, Van Snellenberg JX, Sepehry AA, et al. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol. 2006;20(3):335–46. [PubMed: 16174678]
548.
Tilden D, Aristides M, Meddis D, et al. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clin Ther. 2002;24(10):1648–67. [PubMed: 12462294]
549.
Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol. 2007;22(5):315–25. [PubMed: 17542047]
550.
Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000;2(3:Pt 2):8. [PubMed: 11249804]
551.
Tohen M, Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord. 2009;11(Suppl 54) [PubMed: 19538685]
552.
Tohen M. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997. pp. 1997–22.
553.
Tohen M. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. 150th Annual Meeting of the American Psychiatric Association; 1997.
554.
Tohen MF, Zhang F, Feldman PD, et al. Olanzapine versus haloperidol treatment of acute mania. Ann Meet Am Psychiatr Assoc. 2001
555.
Tohen MF, Zhang F. Olanzapine versus haloperidol in schizoaffective bipolar disorder: a repeated-measures analysis. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999. p. 20.
556.
Tohen MF. Olanzapine versus haloperidol treatment of acute mania. 155th Annual Meeting of the American Psychiatric Association; 2002.
557.
Tollefson G. The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the typical antipsychotic olanzapine. 9th European College of Neuropsychopharmacology Congress; 1996.
558.
Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. The American Journal of Psychiatry. 1997;(9):1248–54. [PubMed: 9286184]
559.
Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol: results of the multi-centre international trial conference proceeding. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia; 1996.
560.
Tollefson GD, Lu Y. A blinded trial on the course and relationship of depressive symptoms in schizophrenia conference abstract. 150th Annual Meeting of the American Psychiatric Association; 1997.
561.
Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Eur Neuropsychopharmacol. 2006;6(3):58.
562.
Tollefson GD. The value of atypical antipsychotic medications conference abstract. 150th Annual Meeting of the American Psychiatric Association; 1997.
563.
Tran P. Acute and long-term results of the North American double-blind olanzapine trial. Eur Neuropsychopharmacol. 1995;5(Supplement 1):347–8.
564.
Tran P. Olanzapine in the treatment of schizoaffective disorder. Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia; 1998.
565.
Tran P. Olanzapine versus haloperidol: acute results of the multi-center international trial. XXth Collegium Internationale Neuro-psychopharmacologicum; 2006.
566.
Tran P. Olanzapine versus haloperidol: results of the international trial. 9th European College of Neuropsychopharmacology Congress; 1996.
567.
Tran PV, Beasley CM, Tollefson GD, et al. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent. Meeting of the American Psychiatric Association; Washington, DC, USA. 1999.
568.
Tran PV, Beasley CM, Tollefson GD, et al. Olanzapine: a promising “Atypical” antipsychotic agent conference abstract. Schizophrenia Research (The Vth International Congress on Schizophrenia Research); Wormsprings, VA USA. 1995. p. 169.
569.
Tran PV, Creanga D. Clinical experience with olanzapine in ethnic subgroups. NCDEU; Boca Raton, FL, USA: 1999.
570.
Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997;58(5):205–11. [PubMed: 9184614]
571.
Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499–505. [PubMed: 9828990]
572.
Tran PV, Jakovljevic M. Olanzapine versus fluphenazine: treatment of acute schizophrenic symptomatology and anxiety. Biol Psychiatry. 1998;43:109S.
573.
Tran PV, Tollefson GD, Crawford AM, et al. Olanzapine versus fluphenazine in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998.
574.
Tran PV, Zhang F. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of chinese patients with schizophrenia in taiwan and hong. 152nd Annual Meeting of the American Psychiatric Association; 1999.
575.
Tulloch KJ, Zed PJ. Intramuscular olanzapine in the management of acute agitation. Ann Pharmacother. 2004;38(12):2128–35. [PubMed: 15522977]
576.
Tunis SL, Johnstone BM, Gibson PJ, et al. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry. 1999;60(Suppl 45) [PubMed: 10507279]
577.
Tys SM, Vlokh IY. Influence of risperidone very small doses on the negtive symptoms in schizophrenia conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe, New Mexico, USA. 1999. p. 300.
578.
Umbricht D, Kane JM. Risperidone: efficacy and safety. Schizophr Bull. 1995;21(4):593–606. [PubMed: 8749887]
579.
Vangala SZ. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Hong Kong. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998. p. 16.
580.
Vargas M, Asensio N, Martn S. Effectiveness of antipsychotics in ambulatory schizophrenia: five-year retrospective cohort study. 2009. p. S78.
581.
Veser FH, Zealberg J, Veser BD, et al. Oral risperidone in the management of agitated behaviours in emergency setting. Chicago, Illinois, USA. October 9–13, 2002; Annual Meeting of the American Psychiatric Association Institute on Psychiatric Services.2002.
582.
Volavka J, Citrome L. Olanzapine vs haloperidol for treatment of schizophrenia. JAMA. 2004;291(9):1064–6. [PubMed: 14996765]
583.
Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry. 2005;66(11):1362–6. [PubMed: 16420071]
584.
Volavka J, Nolan KA, Kline L, et al. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophr Res. 2005;76(1):127–9. [PubMed: 15927808]
585.
Volavka J. Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000. p. 14.
586.
Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990–9. [PubMed: 10401441]
587.
Wahlbeck K, Tuunainen A, Gilbody S, et al. Influence of methodology on outcomes of randomised clozapine trials. Pharmacopsychiatry. 2000;33(2):54–9. [PubMed: 10761820]
588.
Wang CH, Zhao Z, Li Y, et al. Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Chin J Clin Rehabil. 2002;6(17):2664–5.
589.
Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2:Suppl 1):9. [PubMed: 18334908]
590.
Weiser M, Shneider-Beeri M, Nakash N, et al. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res. 2000;46(2–3):81–9. [PubMed: 11120419]
591.
Williams LM, Loughland CM, Green MJ, et al. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry Res. 2003;120(1):13–27. [PubMed: 14500110]
592.
Windhaber J, Urbanits S, Grisold W. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 2000;54(7):1543–4. [PubMed: 10751282]
593.
Winlow W, Profit L, Chrisp P. Aripiprazole: the evidence of its therapeutic impact in schizophrenia. Core Evid. 2006;1(4):251–64. [PMC free article: PMC3321669] [PubMed: 22496680]
594.
Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):856–65. [PubMed: 12416594]
595.
Wirshing DA, Marder SR, Wirshing WC. Subjective response to atypical antipsychotic medications conference abstract. Schizophrenia Research (Abstracts of The VIIth International Congress on Schizophrenia Research); Santa Fe New Mexico USA. 1999. pp. 17–21.
596.
Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60(6):358–63. [PubMed: 10401912]
597.
Wirshing WC, Ames D. Risperidone versus haloperidol in treatment-refractory schizophrenia: preliminary results. Psychopharmacol Bull. 1995;(3):633.
598.
Wirshing WC, Ames D. Risperidone vs haloperidol in treatment resistant schizophrenia: preliminary results conference proceeding. Schizophrenia Research (VIIIth Biennial Winter Workshop on Schizophrenia); 1996. p. 130.
599.
Wolwer W. Effects of risperidone vs. haloperidol on neurocognition in first-episode schizophrenia: results from a rct. Int J Neuropsychopharmacol. 2008;(Suppl 1):159.
600.
Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–7. [PubMed: 12823080]
601.
Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1–3):211–24. [PubMed: 17059880]
602.
Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457–72. [PubMed: 15784157]
603.
Wright P. A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Schizophr Res. 2001;49(2 Suppl 1):250–1.
604.
Wright P. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Int J Neuropsychopharmacol. 2000;(Suppl 1):S139.
605.
Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59(4):385–94. [PubMed: 16048443]
606.
Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003;20(4):339–46. [PMC free article: PMC1726160] [PubMed: 12835344]
607.
Yocca F. Intramuscular aripiprazole in acute schizophrenia: a pivotal phase-three study. 158th Annual Meeting of the American Psychiatric Association; 2005.
608.
Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther. 2010;32(3):403–25. [PubMed: 20399981]
609.
Zhang B. A 4-week, randomized, rater-blinded, parallel-group, haloperidol-controlled study to evaluate the efficacy of quetiapine fumarate in improving sleep quality in the patients with schizophrenia. Int J Neuropsychopharmacol. 2010:113–4.
610.
Zhang F. Olanzapine versus haloperidol: assessment of cognitive function in patients with schizoaffective disorder, bipolar type. Eur Neuropsychopharmacol. 1999;9(Suppl 5):247.
611.
Zhang XY, Zhou DF, Shen YC. Effects of risperidone and haloperidol on paroxetine-evoke neuroendocreine responses in schizophrenia. Schizophrenia Research (Xth Biennial Winter Workshop on Schizophrenia); 2000. p. 11.
612.
Zinner HJ, Fuger J. Changes of positive and negative syndromes: a double-blind clinical trial with risperidone versus haloperidol in chronic schizophrenia. Pharmacopsychiatry. 1992;25:118.

Non-English Language Publication

1.
Adrianzen C. Olanzapine versus haloperidol: effectiveness in functionality and health state in a sample of Venezuelan patients with schizophrenia. Vertex. 2008;(81):254–60. [PubMed: 19835025]
2.
Ai L. A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia. Heilongjiang Med J. 2007;(4):285.
3.
An QH, Hu KY, Meng XL. A comparison of intelligence disorders and memory disorders in the first-onset schizophrenia treated with quetiapine and chlorpromazine. Chin J Behav Med Sci. 2005;(1):62–3.
4.
Ao X. Comparative study between aripiprazole and chlorpromazine in the treatment of female patients with schizophrenia. Med J Chin Civil Admin. 2006;(17):719–20.
5.
Bai Y. A random chlorpromazine-controlled study of the effects of quetiapine on cognition in schizophrenia. Shanghai Arch Psychiatry. 2005;(3):151–4.
6.
Bian QT, Xie GR. A comparative study of quality of life in schizophrenia treated with chlorpromazine, clozapine or risperidone. Chin J Clin Psychol. 2003;(2):125–7.
7.
Blaeser-Kiel G. Schizophrenes negativsyndrom risperidone erfolgreich. Neurologie Psychiatrie. 1994;(11):614–5.
8.
Bouchard RH. Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation. L’Encephale. 2002;2 [PubMed: 12587355]
9.
Cao D. Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chin J Clin Rehabil. 2005;(36):63–8.
10.
Cao D. Comparison of the effects of chlorpromazine, risperidone and quetiapine on hypothalamic-pituitary-gonodal axis and sexual function in male patients with schizophrenia. Chin J Rehabil. 2005;(20):148–51.
11.
Cao KS, Yao J. Safety and efficacy of ziprasidone and haloperidol in patients with schizophrenia. Chin J New Drug Clin Remed. 2006;(6):431–4.
12.
Ceskova E, Svestka Efficacy and tolerance of risperidone in various doses (report of a study) Ceska Slov Psychiatr. 1996;(1):50–6. Purkyne. [PubMed: 8768938]
13.
Chang FW, Wang CH, Zhao Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chin J New Drug Clin Remed. 2003;(6):357–9.
14.
Chang SH. Comparative study of loxapine and risperidone in the treatment of schizophrenia. Med J Chin People Health. 2006;(12):1020–1.
15.
Chen Q. A comparative study of the effects of clozapine, risperidone and chlorpromazine on sugar metabolism in schizophrenic treatment. Chin J Clin Health Psychol. 2007;(4):382–3.
16.
Cheng XF. Control observation of quetiapine vs chlorpromazine in schizophrenia. J Clin Psychosom Dis. 2003;(2):78–80.
17.
Chung YC, Park KH, Kim DJ, et al. Prolactin response to the administration of risperidone and haloperidol in patients with schizophrenia and other psychotic disorders. Korean J Psychopharmacol. 2000;(4):343–9.
18.
Cui B. A comparative study of the effects of risperidone, chlorpromazine and clozapine to patients with schizophrenia by the electrocardiograms. Tianjin Pharm. 2002:55.
19.
Cui LI, Tian G. Serum levels of prolactin and growth hormone and effect of pharmacotherapy on schizophrenia: a comparative study of risperidone and chlorpromazine. Chin Ment Health J. 1999;(6):368–70.
20.
Dongfeng Z. Effects of risperidone and haloperidol on paroxetine-evoked neuroendocrine responses in schizophrenia. Chin J Psychiatry. 1999;(2):84–7.
21.
Du BG, Fang RL. Control studies on curative effects of loxapine succinate and risperidone in schizophrenics. J Clin Psychosom Dis. 2003;(1):16–9.
22.
Du QX, Yu CF, Zhong A clinical comparative analysis of quetiapine and chlorpromazine in treatment of schizophrenia. Med J Chin People Health. 2004;(7):398–9.
23.
Fan J. Effect of risperidone and chlorpromazine on cognition in first-episode schizophrenia. Chin J Clin Health Psychol. 2006;(4):422–4.
24.
Feng CX, Huang SX, Yang HZ. A comparative trial on the efficacy of risperidone vs chlorpromazine in treatment-resistant schizophrenia. Shandong Arch Psychiatry. 2001;(2):95–6.
25.
Gaszner P. Clinical observations with aripiprazole in schizophrenia. Neuropsychopharmacol Hung. 2006;(1):29–32. [PubMed: 16841563]
26.
Ge Q. A comparative study of risperidone combining clonazepam and haloperidol in the treatment of patients with schizophrenia. Shandong Arch Psychiatry. 2004;(3):134–6.
27.
Guo BY, Wang YB. Control studies on efficacy of quetiapine vs chlorpromazine in first- episode schizophrenics. J Clin Psychosom Dis. 2003;(2):75–7.
28.
Guo J. Effect of quetiapine and chlorpromazine on cognitive function in first-episode schizophrenic. Chin J Clin Health Psychol. 2007;(7):583–4.
29.
He M. A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia. Chin New Drugs J. 1999;(3):185–7.
30.
He YD, Zhao CM, Shao AL, et al. A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia. Herald Med. 2003;(10):680–2.
31.
Hou YZ, Guo JH, Zhou The double-blind study of risperidone and haloperidal in the treatment of schizophrenia. Shanghai Psychol Med. 2001;(3):149–51.
32.
Huang J. Comparison of compliance and effectiveness of quetiapine and haloperidol in the treatment of schizophrenia. Int Med Health Guid News. 2007;(16):96–9.
33.
Huang SX, Feng CX, Chen JY, et al. Risperidone vs chlorpromazine in treating schizophrenia: a randomized double-blind study. Chin J New Drug Clin Remed. 2000;(5):396–8.
34.
Jager M. Pharmacological acute treatment in first episode schizophrenic disorders. Nervenheilkunde. 2006;(1–2):32–6.
35.
Jarema M. Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial. Psychiatr Pol. 2003;(4):641–55. [PubMed: 14560493]
36.
Ji J. Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine. Sichuan Ment Health. 2004;(2):73–5.
37.
Jiang KD, Bai YL, Peng DH, et al. A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia. Linchuang Jingshen Yixue Zazhi. 2006;(6):352–3.
38.
Jin SL. Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial. China Pharm. 2007;(19):56–7.
39.
FenYing Ju, DongSheng Zhu, Lu Wei hong Liu Yan, et al. The randomised control trial of thioridazine and sulpiride treating schizophrenia with negative symptoms. Sichuan Ment Health. 1997;10(3):171–2.
40.
Kong DL, Zhang SQ, Shu MQ. Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics. J Clin Psychosom Dis. 2003;(4):200–1.
41.
Le PC. Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France. L’Encephale. 1999;(4):281–6. [PubMed: 10546082]
42.
Leon CA, Estrada H. Efectors terapeuticos de la clozapina sobre los sintomas de psicosis. Revista Colombiana de Psiquiatria. 1974;3:309–18.
43.
Li C. A controlled study of olanzapine and haloperidol in the treatment of the acute phase of schizophrenia. Shanghai Arch Psychiatry. 2005;(5):275–7.
44.
Li LH, Fang MS, Xu XF, et al. Ziprasidone vs haloperidol in treatment of schizophrenia: a randomized, double-blind, double-dummy, multicenter, parallel control study. Chin J New Drug Clin Remed. 2007;(5):335–8.
45.
Li LXLC. A comparative study of loxapine succinate and risperidone in the treatment of schizophrenia. Shandong Arch Psychiatry. 2005;(4):246–7.
46.
Li Y, Shang J, Li C. Control study of loxapine succinate and clozapine on curative effects in treatment of schizophrenics. Heath Psychology Journal. 2004;12(3):202.
47.
Li Y. A comparative effects of aripiprazole and haloperidol on the cognitive dysfunction in the treatment of first episode schizophrenic patients. Sichuan Ment Health. 2006;(3):150–2.
48.
Li ZYHR. Comparative study between loxapine and risperidone in treatment of schizophrenia. J Clin Psychol Med. 2005;(1):11–2.
49.
Lin HL, Shi WH, Wang JH. Effects of aripiprazole and chlorpromazine on the cognitive function in first-episode schizophrenia patients. Chin J Behav Med Sci. 2006;(5):440–2.
50.
BingLang Liu, Chen YY, Yang DS. Effects of thioridazine on schizophrenics and clinical utility of plasma levels. Chin J Neurol Psychiatry. 1994;27:364–7.
51.
Liu BL, Chen YY, Yang DS. Effects of thioridazine on schizophrenics and clinical utility of plasma levels. Chin J Neurol Psychiatry. 1994;27:364–7.
52.
Liu G. A comparative study on risperidone and perphenazine in the treatment of schizophrenic patients. Shandong Arch Psychiatry. 2001;(3):170–2.
53.
Liu Y. A comparative study of risperdal and chlorpromazine in the treatment of the negative symptoms of schizophrenia. Herald Med. 2000;(4):323–4.
54.
Lopez Ibor JJ, Ayuso JL, Gutierrez Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1996;(4):165–72. [PubMed: 8984849]
55.
Lu X-Q, Zhu G-L. Control studies of loxapine succinate and clozapine in treatment of schizophrenia. J Clin Psychosom Dis. 2003;9(3):157–8.
56.
Lu ZD, Cao YN, Wang A comparative study of aripiprazole and chlorpromazine in the treatment of schizophrenia. Shandong Jingshen Yixue. 2006;(2):90–2.
57.
Luo X. Comparison of effects and factors between risperidone and chlorpromazine on schizophrenia. Chin J New Drug Clin Remed. 2001:266.
58.
Ma ZH, Liu AY, Zhou CM, et al. A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Med J Chin People Health. 2004;(4):202–4.
59.
Ma ZW, Li MX, Shi YZ, et al. Quetiapine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia. Chin J New Drug Clin Remed. 2004;(5):273–5.
60.
Mei AC. Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Med J Chin People Health. 2007;(17):723–4.
61.
Murasaki M. Clinical evaluation of quetiapine fumarate on schizophrenia: comparative double-blind study with haloperidol. Seishin Igaku. 2001;(1):127–55.
62.
Murasaki M. Efficacy of a new antipsychotic, risperidone, on schizophrenia: a comparative double blind study with haloperidol. Rinsho Hyoka. 1993;(2):221–59.
63.
Peng YH, Zhu ZX, Yang YX. Effect on prolactin of quetiapine and chlorpromazine in male schizophrenia. Med J Chin Civil Admin. 2006;(9):760–1.
64.
Peng ZG, Zhou JX, Kuang WH, et al. A randomized double - blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China J Pharm Sci. 2006;(6):606–8.
65.
Qin Y. A comparative trial of olanzapine versus haloperidol in the treatment of schizophrenia. Hebei Med. 2006;(10):1011–3.
66.
Qiu Y. A comparative study between quetiapine and haloperidol on the life quality of the patients with schizophrenia. Shandong Arch Psychiatry. 2003;(3):138–40.
67.
Ren QTYJL. Effect of haloperidol and risperidone on the life quality of the patients with schizophrenia. Chin J Clin Psychol. 2002;(2):150–1.
68.
Sheng Y. A comparison study of the blood sugar in the treatment of schizophrenic patients with risperidone, clozapine and chlorpromazine. Qilu Journal of Medicall Aboratory Sciences. 2003;(1):11–2.
69.
Tian H. Comparative study on the effect of seroquel and chlorpromazine on schizophrenia. China Pharmacy. 2006;(9):682–3.
70.
Tu ZM, Deng XP, Ca DM. Comparative study between aripiprazole and chlorpromazine in treatment of schizophrenia. Med J Chin People Health. 2007;(17):715–6.
71.
Wang C. A clinical study of risperidone, clozapine and chlorpromazine in patients with first-episode schizophrenia. J Clin Psychosom Dis. 2006;(1):7–9.
72.
Wang C. Comparative study on the life quality of first-episode schizophrenics treated with risperidone, clozapine and chlorpromazine. J Clin Psychosom Dis. 2006;(2):87–9.
73.
Wang G-P. A comparative study between aripiprazole and chlorpromazine in the treatment of schizophrenia. Shandong Arch Psychiatry. 2005;18(4):250–1.
74.
Wang H. Safety and efficacy of quetiapine and haloperidol in the treatment of schizophrenia with excitement and agitation. Shanghai Arch Psychiatry. 2005;(5):271–4.
75.
Wang LG, Liu Y. A comparative trial of the efficacy on olanzapine and chlorpromazine in treatment-resistant schizophrenia. Heath Psychology Journal. 2004;(3):203–4.
76.
Wang LG, Wang DM, Su A comparative study of aripiprazole and haloperidol in the treatment of patient with treatment-resistant schizophrenia. Nerv Dis Ment Hygjene. 2006;(1):38–9.
77.
Wang Q. Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychol J. 2002;(3):226–8.
78.
Wang RC, Li LH, Zhao YC. Ziprasidone made in China and haloperidol in treating acute onset of schizophrenia: a randomized, single blinded, double modelling, parallel control study. Chin J Clin Rehabil. 2005;(44):83–5.
79.
Wang X. Effect of chlorpromazine and risperidone on coginition function of the patients with first episode schizophrenia. Heath Psychology Journal. 2005;(5):342–4.
80.
Wang. Control study of loxapine and quetiapine treating first onset schizophrenia. Chin J Behav Med Sci. 2005;14(8):752.
81.
Wu SX. A comparative trial on the efficacy of risperidone vs chlorpromazine in chronic schizophrenia. Health Psychol J. 2002;(5):364–5.
82.
Wu Y. A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenica. Shandong Arch Psychiatry. 2004;(3):137–40.
83.
Xia SYHP. A treatment study of schizophrenia with aripiprazole and chlorpromazine. Pract Clin Med. 2005;(10):33–4.
84.
Xia SYWC. A comparison between the therapeutic effectiveness and safeness of aripiprazole and chlorpromazine in the treatment of first-episode schizophrenia. Herald Med. 2007;(6):619–20.
85.
Xu WR, Bao-Long Z, Qui C. A double-blind study of clozapine and chlorpromazine treatment in the schizophrenics. Chin J Nerv Ment Dis. 1985;11:222–4.
86.
Yang B. Effects of clozapine, risperidone and haloperidol on plasma leptin in first-episode schizophrenic patients. J Fourth Mil Med Univ. 2004;(14):1323–5.
87.
Yu J. A comparison of cognitive function in schizophrenia treated with risperidone and chlorpromazine. J Clin Psychol Med. 2001;(5):265–6.
88.
Zhang F. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: a repeated measures analysis conference abstract. Schizophr Res. 1999;(303):17–21.
89.
Zhang HY, Wang X. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chin J Clin Pharmacol. 2003;(3):163–6.
90.
Zhang SL. A double-blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia. Shandong Arch Psychiatry. 2002;(3):149–51.
91.
Zhang WMJG, Xu FL. Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine. Heilongjiang Med J. 2006;(2):81–2.
92.
Zhang X. The effect of risperidone and haloperidol treatment on plasma interleukin 2, 6, 8 in inpatients with schizophrenia and their relationship to outcome. Chin J Nerv Ment Dis. 2000;(4):222–4.
93.
Zhao JP, Chen JD, Chen YG, et al. A double-blind and double-dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Chin New Drugs J. 2002;(2):149–51.
94.
Zhao Z. A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. Chin J Clin Health Psychol. 2006;(1):41–2.
95.
Zheng X. A double blind comparing study between the effects of haloperidol and olanzapine on the quality of life of the patients with schizophrenia. J Jining Med Coll. 2004;(3):20–2.
96.
Zheng ZB, Ma ZF, Zhang LL. A comparative study of the effects of olanzapine and perphenazine on schizophrenia and the patients’ quality of life. J Linyi Med Coll. 2004;(4):273–5.
97.
Zhou J. Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients. Chin Ment Health J. 2003;(10):699–1.
98.
Zhou M. Double-blind comparison between risperidone and haloperidol in the treatment of schizophrenic patients. Chin J Clin Pharmacol. 2002;(5):341–4.
99.
Zhou SB, Sun XD, Li YM. A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia. Med J Chin People Health. 2004;(11):657–9.
100.
Zou JH, Zhou Y. A clinical analysis between quetiapine and haloperidol in the treatment of schizophrenia. Med J Chin People Health. 2007;19(11):434–7.

Population and Intervention Characteristics

1.
Advokat C, Hill BD, Comaty JE. ‘Real world’ comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations. Psychiatr Q. 2008;79(1):55–64. [PubMed: 18060498]
2.
Akkaya C, Sarandol A, Cangur S, et al. Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. Hum Psychopharmacol Clin Exp. 2007;22(8):515–28. [PubMed: 17868197]
3.
Altamura AC, Velona I, Curreli R. Olanzapine in the traetment of paranoid schizophrenia. Eur Neuropsychopharmacol. 2002;9(Suppl5):S297.
4.
Alvarez E, Bobes J, Gomez JC, et al. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: a naturalistic study. Eur Neuropsychopharmacol. 2003;13(1):39–48. [PubMed: 12480121]
5.
Appelberg B, Tuisku K, Joffe G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics?: a prospective, randomised study with olanzapine. Eur Psychiatry. 2004;19(8):516–8. [PubMed: 15589715]
6.
Archibald DG, Manos G, Tourkodimitris S. Reduction in negative symptoms of schizophrenia during long term therapy with aripiprazole. Schizophr Res. 2003;60(Suppl1):271.
7.
Ascher-Svanum H, Stensland MD, Kinon BJ, et al. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol. 2005;19(6:Suppl):7. [PubMed: 16280344]
8.
Barbui C, Accordini S, Nosè M, et al. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: A randomized, controlled trial. J Clin Psychopharmacol. 2011;31(3):266–73. [PubMed: 21508849]
9.
Bisconer SW, Harte BM. Patterns and prevalence of metabolic syndrome among psychiatric inpatients receiving antipsychotic medications: Implications for the practicing psychologist. Prof Psychol Res Pract. 2010;41(3):244–52.
10.
Bobes J, Gibert J, Ciudad A, et al. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):473–81. [PubMed: 12691783]
11.
Bobo WV, Jayathilake K, Lee MA, et al. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Res. 2010;176(2–3):114–9. [PubMed: 20199813]
12.
Bond GR, Kim HW, Meyer PS, et al. Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics. Psychiatr Serv. 2004;55(1):59–66. [PubMed: 14699202]
13.
Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. J Clin Psychopharmacol. 2000;20(3):295–304. [PubMed: 10831015]
14.
Brar JS, Parepally H, Chalasani L, et al. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. Ann Clin Psychiatry. 2008;20(3):139–44. [PubMed: 18633740]
15.
Brewer WJ, Yucel M, Harrison BJ, et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust NZ J Psychiatry. 2007;41(2):129–35. [PubMed: 17464690]
16.
Broich K, Grunwald F, Kasper S, et al. D2-dopamine receptor occupancy measured by IBZM-spect in relation to extrapyramidal side effects. Pharmacopsychiatry. 1998;31(5):159–62. [PubMed: 9832346]
17.
Brugnoli R, Novick D, Frediani S, et al. Efficacy of antipsychotic treatment in schizophrenia: Results after 24 months in Italian patients in the Schizophrenia Outpatient Health Outcomes (SOHO) study. Ital J Psychopathol. 2007;13(3):330–40.
18.
Carlson C, Hornbuckle K, DeLisle F, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol. 2006;16(5):366–75. [PubMed: 16356695]
19.
Carrasco JL, Gutierrez M, Gomez JC, et al. Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs. Int Clin Psychopharmacol. 2002;17(6):287–95. [PubMed: 12409682]
20.
Carson WH, Pigott TA, Saha AR. Aripirazole versus placebo in the treatment of chronic schizophrenia. 2002. p. S187. [abstract]
21.
Castle DJ, Udristoiu T, Kim CY, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry. 2009;10(1):43–53. [PubMed: 19137460]
22.
Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J Clin Psychiatry. 2009;70(1):122–9. [PubMed: 19192473]
23.
Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry. 1999;60(12):850–6. [PubMed: 10665632]
24.
Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69–73. [PubMed: 18204344]
25.
Costa AMN, De Lima MS, Faria M, et al. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol. 2007;21(2):165–70. [PubMed: 17329296]
26.
Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229–40. [PubMed: 15279042]
27.
Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004;65(3):386–94. [PubMed: 15096079]
28.
Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62(3):153–7. [PubMed: 11305699]
29.
Czekalla J, Dittmann RW, Holstein W, et al. Olanzapine (Zyprexa) treatment in patients pre-treated with other antipsychotics: pharmacovigilance data from a large drug utilization observation (DUO) study in Germany. Germ J Psychiatry. 2005;8(3):49–59.
30.
Daniel DG, Saha AR, Ingenito GG. Aripiprazole, a novel antipsychotic: overview of a phase II study result. Int J Neuropsychopharmacol. 2000;3(Suppl1):S157.
31.
Daniel DG, Zimbroff DL, Swift RH, et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004;19(1):9–15. [PubMed: 15101564]
32.
Daniel J, Chamberlain J, Castle DJ. The pharmacological management of behavioural disturbance in psychosis: a naturalistic study. Australas Psychiatry. 2007;15(5):380–4. [PubMed: 17828634]
33.
Daskalakis ZJ, Christensen BK, Chen R, et al. Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. Psychopharmacology (Berl) 2003;170(3):255–62. [PubMed: 12904966]
34.
De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1–3):295–303. [PubMed: 18299188]
35.
Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354–60. [PubMed: 15096075]
36.
Diehl A, Reinhard I, Schmitt A, et al. Does the degree of smoking effect the severity of tardive dyskinesia?: a longitudinal clinical trial. Eur Psychiatry. 2009;24(1):33–40. [PubMed: 18774276]
37.
Dittmann RW, Geuppert MS, Diehl Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomised double-blind trial. Schizophr Res. 2001;(1–2):225.
38.
Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103–8. [PubMed: 11772697]
39.
Dose M, Glaser T, Weinmuller B. Treating schizophrenia patients with antipsychotics in a naturalistic setting: a retrospective chart review. Psychiatrie. 2008;12(4):197–200.
40.
Emsley R, Rabinowitz J, Medori R, et al. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1–3):129–39. [PubMed: 17095194]
41.
Engelborghs S, Holmes C, McCulley M, et al. 5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(11):1108–9. [PubMed: 15497194]
42.
Freeman HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol. 1997;12(Suppl7) [PubMed: 9218163]
43.
Gaertner I, Altendorf K, Batra A, et al. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001;21(2):215–22. [PubMed: 11270919]
44.
Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58(1):62–6. [PubMed: 15992524]
45.
Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl) 1978;59(2):105–12. [PubMed: 103110]
46.
Gilbody SM, Bangall AM, Duggan L. Risperidone versus other atypical antipsychotic medication for schizophrenia. The Cochrane Collaboration. 2000;(3) [PubMed: 10908551]
47.
Godleski LS, Goldsmith LJ, Vieweg WV, et al. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry. 2003;64(2):119–22. [PubMed: 12633119]
48.
Guha P, Roy K, Sanyal D, et al. Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics. J Indian Med Assoc. 2005;103(12):660–4. [PubMed: 16821658]
49.
Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand. 2005;111(3):220–31. [PubMed: 15701107]
50.
Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235–44. [PubMed: 17137759]
51.
Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–9. [PubMed: 14709949]
52.
Harvey PD, Endicott JM, Loebel AD. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. Bipolar Disord. 2008;(8):900–6. [PubMed: 19594505]
53.
Hassan M, Madhavan SS, Kalsekar ID, et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann Pharmacother. 2007;41(11):1812–8. [PubMed: 17925501]
54.
Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007;32(12):2561–9. [PubMed: 17375138]
55.
Hayhurst KP, Drake RJ, Lewis SW. Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. J Psychopharmacol. 2010;24(1):83–9. [PubMed: 18719041]
56.
Herrera JN, Sramek JJ, Costa JF, et al. High potency neuroleptics and violence in schizophrenics. J Nerv Ment Dis. 1988;176(9):558–61. [PubMed: 3418329]
57.
Heydebrand G, Weiser M, Rabinowitz J, et al. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68(1):1–9. [PubMed: 15037334]
58.
Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006;86(1–3):138–46. [PubMed: 16793238]
59.
Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5(4):437–40. [PubMed: 8998394]
60.
Hummer M, Sperner-Unterweger B, Kemmler G, et al. Does eosinophilia predict clozapine induced neutropenia? Psychopharmacology (Berl) 1996;124(1–2):201–4. [PubMed: 8935817]
61.
Inada T, Murasaki M. The drug induced extrapyramidal symptoms scale: differentiation of extrapyramidal symptom profile and identification of favourable extrapyramidal symptom profile of quetiapine in Japanesepatients. Eur Neuropsychopharmacol. 2001;11(Suppl3):S265.
62.
Jerrell JM, Ramirez PM. Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications. Hum Psychopharmacol Clin Exp. 2008;23(7):595–604. [PubMed: 18680213]
63.
Joffe G, Sintonen H, Appelberg B. Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study. Int J Technol Assess Health Care. 2008;24(4):399–402. [PubMed: 18828933]
64.
Jones B, Tollefson GD. Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia. Schizophr Res. 1998;29:150–1.
65.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry. 2006;63(10):1079–87. [PubMed: 17015810]
66.
Keck PEJr, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005;66(5):611–6. [PubMed: 15889948]
67.
Kelly DL, Weiner E, Ball MP, et al. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23(4):436–41. [PMC free article: PMC3718069] [PubMed: 18583442]
68.
Kennedy E, Song F, Hunter R. Risperidone versus typical antipsychotic medication for schizophrenia. The Cochrane Collaboration. 2000;(2) [PubMed: 10796543]
69.
Kennedy J, Tien YY, Cohen LJ, et al. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. Clin Ther. 2009;31(12):2931–9. [PubMed: 20110033]
70.
Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2009;24(4):181–8. [PubMed: 19451828]
71.
Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833–40. [PubMed: 11105736]
72.
Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33(6):711–7. [PubMed: 18395353]
73.
Kufferle B, Brucke T, Topitz-Schratzberger A, et al. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res. 1996;68(1):23–30. [PubMed: 9027930]
74.
Kujawa M, Saha AR, Ingenito GG. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol. 2002;5(1):S186–S187. [abstract]
75.
Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995;118(1):52–6. [PubMed: 7597122]
76.
Lambert MT, Copeland LA, Sampson N, et al. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(5):919–23. [PubMed: 16581171]
77.
Lauriello J, Kainer J, Hochfeld M, Torres R. Extrapyramidal symtom and akathesia profile of iloperidone in schizophrenia clinical trials. Austin, TX: American College of Clinical Pharmacy; Oct 17–20, 2010. 2010.
78.
Lee C, Wu KH, Habil H, et al. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust NZ J Psychiatry. 2006;40(5):437–45. [PubMed: 16683970]
79.
Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999;37(1):1–11. [PubMed: 10227103]
80.
Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005;88(Suppl3):S43–S52. [PubMed: 16858942]
81.
Letmaier M, Schreinzer D, Reinfried L, et al. Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. Int J Neuropsychopharmacol. 2006;9(5):529–37. [PubMed: 16191207]
82.
Lieberman JA, Philipp M, Kong L. Efficacy and safety of clozapine versus chlorpromazine in first episode psychosis: result of a 52-week randomized double-blind trial. Schizophr Res. 2001;49:236.
83.
Lipkovich IA, Deberdt W, Csernansky JG, et al. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry. 2009;9:44. [PMC free article: PMC2717959] [PubMed: 19602273]
84.
Loebel AD, Khanna S, Rajadhyaksha Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study. J Clin Psychiatry. 2007;(9):1333–8. [PubMed: 17915970]
85.
Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of General Psychiatry. 2001;58(12):1172–6. [PubMed: 11735847]
86.
Mahmoud R, Engelhart L, Ollendorf D, et al. The risperidone outcomes study of effectiveness (ROSE): a model for evaluating strategies in typical psychiatric practice. J Clin Psychiatry. 1999;60(Suppl 3):42–8. [PubMed: 10073377]
87.
Mahmoud RA, Engelhart LM, Janagap CC, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest. 2004;24(5):275–86. [PubMed: 17503889]
88.
Malla AK, Norman RMG, Scholten DJ, et al. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry. 2001;62(3):179–84. [PubMed: 11305704]
89.
Mann K, Bartels M, Gartner HJ, et al. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol: results of an open and crossover study. Pharmacopsychiatry. 1987;20(4):155–9. [PubMed: 2886997]
90.
Mari JDJ, Lima MS, Costa AN, et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):356–61. [PubMed: 15538607]
91.
McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006;189:433–40. [PubMed: 17077434]
92.
Meehan k, Wang H, David S, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494–504. [PubMed: 11927174]
93.
Mehta S, Johnson ML, Chen H, et al. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010;71(6):689–98. [PubMed: 20573328]
94.
Meltzer HY, Bastani B, Kwon KY. A prospective study of clozapine in treatment-resistant schizophrenic patients: preliminary report. Psychopharmacology (Berl) 1989;99:S68–S72. [PubMed: 2813667]
95.
Meltzer HY, Bobo WV, Lee MA, et al. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res. 2010;177(3):286–93. [PubMed: 20378185]
96.
Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69–75. [PubMed: 9501888]
97.
Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry. 2001;62(12):975–80. [PubMed: 11780879]
98.
Mojtabai R, Lavelle J, Joseph GP, et al. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr Bull. 2003;29(3):519–30. [PubMed: 14609245]
99.
Montes JM, Ciudad A, Gascon J, et al. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):667–74. [PubMed: 12787855]
100.
Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491–8. [PubMed: 15554761]
101.
Moore DB, Kelly DL, Sherr JD, et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health-Syst Pharm. 1998;55(24:Suppl 4):S17–S19. [PubMed: 9872689]
102.
Murasaki M. Efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Int J Neuropsychopharmacol. 2000;(Suppl 1):S150.
103.
Nakonezny PA, Byerly MJ. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res. 2006;82(1):107–14. [PubMed: 16376522]
104.
Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997–2004. [PMC free article: PMC3055629] [PubMed: 20520598]
105.
Novick D, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531–40. [PubMed: 20814320]
106.
Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Eur Neuropsychopharmacol. 2009;(8):542–50. [PubMed: 19500949]
107.
Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108(1–3):223–30. [PubMed: 19070991]
108.
Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124(1–2):188–96. [PubMed: 8935815]
109.
Peralta V, Campos MS, de Jalon EG, et al. DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res. 2010;118(1–3):168–75. [PubMed: 20071147]
110.
Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. New Engl J Med. 2009;360(3):225–35. [PMC free article: PMC2713724] [PubMed: 19144938]
111.
Ritsner MS, Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1442–52. [PubMed: 16842897]
112.
Rollnik JD, Borsutzky M, Huber TJ, et al. Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiology. 2002;45(2):74–80. [PubMed: 11893863]
113.
Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999;52(4):782–5. [PubMed: 10078728]
114.
Rothschild AJ, Bates KS, Boehringer KL, et al. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999;60(2):116–8. [PubMed: 10084638]
115.
Sacchetti E, Turrina C, Parrinello G, et al. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol. 2005;20(1):33–7. [PubMed: 15602114]
116.
Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561–6. [PubMed: 11925293]
117.
Shafti SSSB. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010;(1):44–7. [PubMed: 20075647]
118.
Shi L, Juarez R, Hackworth J, et al. Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin. 2006;22(5):961–6. [PubMed: 16709317]
119.
Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29(1):133–45. [PubMed: 14583740]
120.
de Silva LM, de Jesus MJ, Breier A, et al. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry. 2005;66(7):831–8. [PubMed: 16013897]
121.
Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47(7):671–5. [PubMed: 12355680]
122.
Stargardt T, Weinbrenner S, Busse R, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Mental Health Policy Econ. 2008;11(2):89–97. [PubMed: 18509216]
123.
Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophr Res. 2006;84(1):77–89. [PubMed: 16483745]
124.
Tsirigotis K, Gruszczynski W. Needs and values of outpatients with schizophrenia, treated with classic neuroleptics and risperidone. Arch Psychiatr Psychother. 2004;6(3):37–51.
125.
Tsirigotis K, Gruszczynski W. Personality functioning of outpatients with schizophrenia treated with classic neuroleptics and risperidone. Arch Psychiatr Psychother. 2004;6(3):23–36.
126.
Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, I-year trial. Value Health. 2006;9(2):77–89. [PubMed: 16626411]
127.
Van Praag HM, Korf J, Dols LC. Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. Br J Psychiatry. 1976;129:547–55. [PubMed: 1000139]
128.
Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64(5):524–31. [PubMed: 12755654]
129.
Veser FH, Veser BD, McMullan JT, et al. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract. 2006;12(2):103–8. [PubMed: 16728906]
130.
Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405–13. [PubMed: 17900775]
131.
Weiden P, Glazer W. Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q. 1997;68(4):377–92. [PubMed: 9355136]
132.
Wetter TC, Lauer CJ, Gillich G, et al. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiatr Res. 1996;30(6):411–9. [PubMed: 9023785]
133.
Wirz-Justice A, Haug HJ, Cajochen C. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophr Bull. 2001;27(3):497–502. [PubMed: 11596850]
134.
Wittorf A, Sickinger S, Wiedemann G, et al. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Arch Clin Neuropsychol. 2008;23(3):271–82. [PubMed: 18272323]

No Extractable Data Related to Outcomes of Interest

1.
Apiquian R, Fresan A, Herrera K, et al. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. Int J Neuropsychopharmacol. 2003;6(4):403–8. [PubMed: 14604455]
2.
Atmaca M, Kuloglu M, Tezcan E, et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res. 2003;60(1):99–100. [PubMed: 12505146]
3.
Bitter I, Czobor P, Dossenbach M, et al. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO) Eur Psychiatry. 2005;20(5–6):403–8. [PubMed: 16084068]
4.
Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61(12):933–41. [PubMed: 11206599]
5.
Bustillo JR, Lauriello J. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res. 2002;(2–3):313–21. [PubMed: 12409172]
6.
Bustillo JR, Rowland LM, Jung Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology. 2008;(10):2456–66. [PubMed: 18094668]
7.
Castro AP, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr. 2007;29(3):207–12. [PubMed: 17891257]
8.
Ceskova E, Svetska J. Risperidone vs. perphenazine: a double-blind comparison and prolactin plasma levels. Psychiatr Danub. 1994;6(3–4):151–5.
9.
Chae BJ, Kang BJ. The effect of clozapine on blood glucose metabolism. Hum Psychopharmacol. 2001;16(3):265–71. [PubMed: 12404579]
10.
Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry. 1988;21(6):295–7. [PubMed: 2907629]
11.
Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: Effects of antipsychotic drugs. Psychiatry Res. 2008;158(2):206–16. [PubMed: 18243335]
12.
Di SG, Calo S, Amodio G, et al. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting. International Journal of Immunopathology & Pharmacology. 2011;24(1):225–30. [PubMed: 21496406]
13.
Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006;21(4):251–8. [PubMed: 16530390]
14.
Dossenbach M, Erol A, el Mahfoud KM, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65(3):312–21. [PubMed: 15096069]
15.
Esel E, Basturk M, Saffet GA, et al. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneuroendocrinology. 2001;26(6):641–7. [PubMed: 11403983]
16.
Garcia-Cabeza I, Gomez JC, Sacristan JA, et al. Subjective response to antipsychotic treatment and compliance in schizophrenia: a naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) BMC Psychiatry. 2001;1:7. [PMC free article: PMC65550] [PubMed: 11835695]
17.
Gerlach J, Koppelhus P, Helweg E, et al. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand. 1974;50(4):410–24. [PubMed: 4153596]
18.
Gerlach J, Thorsen K, Fog R. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia. 1975;40(4):341–50. [PubMed: 1096218]
19.
Gerra G, Di PG, D’Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007;30(3):127–35. [PubMed: 17545747]
20.
Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. J Clin Psychopharmacol. 2011;31(1):82–5. [PubMed: 21192148]
21.
Heh CW, Herrera J, DeMet E, et al. Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology. 1988;1(2):149–56. [PubMed: 3251495]
22.
Hempel RJ, Tulen JH, van Beveren NJ, et al. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. J Psychopharmacol. 2009;23(6):697–707. [PubMed: 18562420]
23.
Herceg M, Jukic V, Vidovic D, et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J. 2008;49(2):215–23. [PMC free article: PMC2359893] [PubMed: 18461677]
24.
Hsu WY, Huang SS, Lee BS, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 2010;30(3):230–4. [PubMed: 20473056]
25.
Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80(1):55–9. [PubMed: 15964176]
26.
Huang TL, Lu CY. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Med J. 2007;30(1):26–32. [PubMed: 17477026]
27.
Hummer M, Kemmler G, Kurz M, et al. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry. 1999;156(4):631–3. [PubMed: 10200746]
28.
Jerrell JM, McIntyre RS, Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clinical Schizophrenia & Related Psychoses. 2010;4(3):161–8. [PubMed: 20880826]
29.
Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005;162(5):939–46. [PubMed: 15863796]
30.
Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–71. [PubMed: 20884948]
31.
Lambert M, Schimmelmann BG, Schacht A, et al. Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol. 2011;31(2):226–230. [PubMed: 21346606]
32.
Lane HY, Guo SC, Hwang TJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol. 2002;22(5):530–2. [PubMed: 12352282]
33.
Lee P, Eung KC, Yoon KC, et al. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Int J Psychiatr Clin Pract. 2008;12(3):215–27. [PubMed: 24931661]
34.
Liew A, Verma S, Lye YP, et al. Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. J Psychopharmacol. 2010;24(7):973–80. [PubMed: 19965942]
35.
Lindenmayer Jean, Pierre Smith RC, et al. Hyperglycemia in patients with schizophrenia who are treated with olanzapine. J Clin Psychopharmacol. 2001;21(3):351–3. [PubMed: 11386505]
36.
Marder SR. Risperidone: clinical development: North American results. Clin Neuropharmacol. 1992;15(Suppl 93A) [PubMed: 1379883]
37.
Nechifor M, Vaideanu C, Palamaru I, et al. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr. 2004;23(5):549S–51S. [PubMed: 15466963]
38.
Olfson M, Marcus SC, scher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379–87. [PMC free article: PMC2779880] [PubMed: 17470444]
39.
Opjordsmoen S, Melle I, Friis S, et al. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early Intervention in Psychiatry. 2009;3(1):58–65. [PubMed: 21352176]
40.
Paunovic VR, Timotijevic I, Marinkovic D. Neuroleptic actions on the thyroid axis: different effects of clozapine and haloperidol. Int Clin Psychopharmacol. 1991;6(3):133–9. [PubMed: 1806619]
41.
Potkin SG, Fleming K, Jin Y, et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol. 2001;21(5):479–83. [PubMed: 11593072]
42.
Ravanic DB, Dejanovic SM, Janjic V, et al. Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period. Arq Neuro-Psiquiatr. 2009;67(2A):195–202. [PubMed: 19547808]
43.
Remillard S, Pourcher E, Cohen H. Long-term skill proceduralization in schizophrenia. J Int Neuropsychol Soc. 2010;16(1):148–56. [PubMed: 19900349]
44.
Remillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res. 2005;80(1):99–106. [PubMed: 16162401]
45.
Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11(2:Pt 2):251–5. [PubMed: 20218789]
46.
Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011;364(9):842–51. [PubMed: 21366475]
47.
Schennach-Wolff R, Jager M, Mayr A, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--Is it all about early response? Eur Neuropsychopharmacol. 2011;21(5):370–378. [PubMed: 21255982]
48.
Schuhmacher A, Mossner R, Quednow BB, et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics. 2009;19(11):843–51. [PubMed: 19794330]
49.
Spivak B, Shabash E, Sheitman B, et al. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003;64(7):755–60. [PubMed: 12934974]
50.
Stoner SC, Wehner Lea JS, Dubisar BM, et al. Impact of clozapine versus haloperidol on conditional release time and rates of revocation in a forensic psychiatric population. J Pharm Technol. 2002;18(4):182–6.
51.
Strassnig M, Miewald J, Keshavan M, et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1–3):90–8. [PMC free article: PMC2100420] [PubMed: 17478082]
52.
Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107(1):1–12. [PMC free article: PMC2675163] [PubMed: 19027269]
53.
Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet. 2009;374(9690):620–7. [PubMed: 19595447]
54.
Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ: British Medical Journal. 2006;333(7561):224. [PMC free article: PMC1523484] [PubMed: 16825203]
55.
Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010;35(6):1315–24. [PMC free article: PMC3055343] [PubMed: 20107430]
56.
Tiwari AK, Zai CC, Meltzer HY, et al. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol. 2010;25(3):253–9. [PubMed: 20373477]
57.
Treuer T, Martenyi F, Saylan M, et al. Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study. Int J Clin Pract. 2010;64(6):697–706. [Erratum appears in Int J Clin Pract. 2010 Sep;64(10):1459] [PubMed: 20345873]
58.
Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res. 1994;13(2):133–44. [PubMed: 7986770]

Unavailable for Review Through Library Services

1.
Atmaca M. The comparison of efficacy of quetiapine and haloperidol in a group of schizophrenic patients with comorbid depressive disorder. Anatol J Psychiatry. 2002;(1):14–9.
2.
Beasley C. Safety Overview of Olanzapine. Xth World Congress of Psychiatry; Madrid, Spain. 2000.
3.
Borison R. Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clin Report. 1991
4.
Cohen BM, Keck PE, Satlin A. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry. 1991;29:1215–9. [PubMed: 1888803]
5.
ddington DE, Arvanitis LA. ‘Seroquel’ (quetiapine): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. Schizophrenia. 1996:1996–9.
6.
He J. A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Arch Psychiatry. 2003;(2):78–80.
7.
Liang J. A comparative study of aripiprazole and haloperidol on quality of life in patients with schizophrenia. Med Inf. 2006;(8):1406–9.
8.
Lieberman JA, Charles C. Effect of olanzapine versus haloperidol on brain pathomorphology in first-episode psychosis. 156th Annual Meeting of the American Psychiatric Association; 2003.
9.
Loebel AD, Warrington L. Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone vs haloperidol treatment in a 40-week core and 3-year double-blind extension study. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006. p. 25.
10.
Lu BH, Su XR, Xie BQ. A comparative study of loxapine and risperidone in the treatment of schizophrenia. Shandong Jingshen Yixue. 2006;(2):122–3.
11.
Qian C. Analysis of therapeutic effect for schizophrenia with risperidone and perphenazine. Acta Uni Med Nahui. 2001;(3):227–9.
12.
Ren Q. A comparative study between perphenazine and risperidone on the effect on the life quality of the patients with schizophrenia. Chin J Behav Med Sci. 2002;(1):32–3.
13.
Rosebush P, Mazurek M. Olanzapine versus haloperidol in randomized trials of first-episode patients with schizophrenia. Stanley Found Res Prog. 2000
14.
Tatossian A. Comparitive double-blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophrenia presenting psychotic anxiety symptoms. Clin Report. 1991
15.
Tran P. Olanzapine vs haloperidol: results of a large multi-centre international trial. Schizophrenia. 1996
16.
Zahn TP, Pickar D. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine. Biol Psychiatry. 1993;34(1–2):3–12. [PubMed: 8104043]
17.
Zhang Z. Comparative clinic analysis of risperidone and haloperidol for treatment of schizophrenic negative symptoms. Int Chin Neuropsychiatry Med J. 2004;(1):37–8.